

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number  
**WO 2004/001000 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number:  
PCT/US2003/019437
- (22) International Filing Date: 20 June 2003 (20.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/390,186 21 June 2002 (21.06.2002) US
- (71) Applicant: **MONSANTO TECHNOLOGY LLC**  
[US/US]; 800 N. Lindbergh Boulevard, St. Louis, MO  
63167 (US).
- (72) Inventor: **FILLATTI, Joanne, J.**; 36757 Russell Blvd.,  
Davis, CA 95616 (US).
- (74) Agents: **MARSH, David, R.** et al.; Arnold & Porter, Attn:  
IP Docketing Dept., Room 1126B, 555 Twelfth Street,  
N.W., Washington, DC 20004-1206 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished  
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 2004/001000 A2**

(54) Title: INTRON DOUBLE STRANDED RNA CONSTRUCTS AND USES THEREOF

(57) Abstract: The present invention is in the field of plant genetics and provides agents capable of gene-specific silencing. The present invention specifically provides double-stranded RNA (dsRNA) agents, methods for utilizing such agents and plants contain- ing such agents.

**INTRON DOUBLE STRANDED RNA CONSTRUCTS AND USES THEREOF****FIELD OF THE INVENTION**

The present invention is in the field of plant genetics and provides agents capable of  
5 gene-specific silencing. The present invention specifically provides double stranded RNA  
(dsRNA) agents, methods for utilizing such agents and plants containing such agents.

**BACKGROUND OF THE INVENTION**

Silencing of genes in plants occurs at both the transcriptional level and post-  
10 transcriptional level. Certain of these mechanisms are associated with nucleic acid homology  
at the DNA or RNA level (Matzke et al., Current Opinion in Genetics and Development,  
11:221-227 (2001)). Double-stranded RNA molecules can induce sequence-specific silencing,  
referred to as RNA interference or RNAi. Fire et al., Nature, 391:806-811 (1988).

**SUMMARY OF THE INVENTION**

15 The present invention includes and provides a nucleic acid construct comprising DNA  
which is transcribed into RNA that forms at least one double-stranded RNA molecule, such  
that one strand of the double-stranded molecule is coded by a portion of the DNA which is at  
least 90% identical to at least one transcribed intron of a gene.

20 The present invention also includes and provides a transformed cell or organism having  
in its genome an introduced nucleic acid construct comprising DNA which is transcribed into  
RNA that forms at least one double-stranded RNA molecule, such that one strand of the  
double-stranded molecule is coded by a portion of the DNA which is at least 90% identical to  
at least one transcribed intron of a gene.

25 The present invention further includes and provides a transformed plant having in its  
genome an introduced nucleic acid construct comprising DNA which is transcribed into RNA

that forms at least one double-stranded RNA molecule, such that one strand of the double-stranded molecule is coded by a portion of the DNA which is at least 90% identical to at least one transcribed intron of a gene.

The present invention includes and provides a method of reducing expression of a protein encoded by a target gene in a mammal comprising introducing into a cell or organism a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, such that one strand of the double-stranded molecule is coded by a portion of the DNA which is at least 90% identical to at least one transcribed intron of a gene.

The present invention includes and provides a method of reducing expression of a protein encoded by a target gene in a plant comprising introducing into a plant genome a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, such that one strand of the double-stranded molecule is coded by a portion of the DNA which is at least 90% identical to at least one transcribed intron of a gene.

The present invention includes and provides a method of altering the expression of a target gene by inserting into a cell or organism a DNA construct for producing a double stranded RNA molecule coding for an intron within the target gene. More particularly, the nucleic acid construct comprises DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, one strand of which is coded by a portion of DNA which is at least 90% identical to at least one transcribed intron of a gene. In a preferred aspect of the invention, one strand of the double-stranded RNA molecule is at least 98%, even more preferably 100% identical, to an intron of a gene.

In one aspect of the invention, a construct for producing double-stranded RNA comprises one strand of an intron, a spliceable intron, and the complement of the intron, such

that the spliceable intron provides a hairpin loop when the intron and the complement of the intron hybridize to each other.

In yet another aspect of this invention the constructs are based on introns within a *FAD2* gene or a *FAD3* gene.

5 In yet another aspect of this invention the construct comprises DNA which is transcribed into double-stranded RNA for at least two transcribed introns, e.g. introns for two or three or more genes.

Another aspect of this invention provides a transformed cell or organism having in its genome a nucleic acid construct which produces a double-stranded RNA of a gene to be  
10 suppressed, e.g., in a plant or an animal, preferably a plant, a mammal, an insect or a nematode. The present invention provides a transformed plant having in its genome a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule such that one strand of the double-stranded molecule is coded by a portion of the DNA which is at least 90% identical to at least one transcribed intron of a native  
15 plant gene or a plant pest gene.

This invention also provides a method of reducing expression of a protein encoded by a target gene in a mammal comprising introducing into a mammalian cell or organism a nucleic acid construct comprising DNA which produces double-stranded RNA based on an intron within a gene to be suppressed. Another aspect of this invention provides a method of  
20 reducing expression of a protein encoded by a target gene in a plant comprising introducing into a plant cell or organism a nucleic acid construct comprising DNA which produces double-stranded RNA based on an intron within a gene to be suppressed.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic of construct pCGN3892.

25 Figure 2 is a schematic of construct pMON70674.

Figure 3 is a schematic of construct pMON70678.

Figure 4 is a schematic of construct pMON68546.

## DETAILED DESCRIPTION OF THE INVENTION

### Description of the Nucleic Acid Sequences

- 5        SEQ ID NO: 1 sets forth a nucleic acid sequence of a *FAD2-1A* intron 1.
- SEQ ID NO: 2 sets forth a nucleic acid sequence of a *FAD2-1B* intron 1.
- SEQ ID NO: 3 sets forth a nucleic acid sequence of a partial *FAD2-2* genomic clone.
- SEQ ID NO: 4 sets forth a nucleic acid sequence of a *FAD2-2B* intron 1.
- SEQ ID NO: 5 sets forth a nucleic acid sequence of a *FAD3-1A* intron 1.
- 10       SEQ ID NO: 6 sets forth a nucleic acid sequence of a *FAD3-1A* intron 2.
- SEQ ID NO: 7 sets forth a nucleic acid sequence of a *FAD3-1A* intron 3A.
- SEQ ID NO: 8 sets forth a nucleic acid sequence of a *FAD3-1A* intron 4.
- SEQ ID NO: 9 sets forth a nucleic acid sequence of a *FAD3-1A* intron 5.
- SEQ ID NO: 10 sets forth a nucleic acid sequence of a *FAD3-1A* intron 3B.
- 15       SEQ ID NO: 11 sets forth a nucleic acid sequence of a *FAD3-1A* intron 3C.
- SEQ ID NO: 12 sets forth a nucleic acid sequence of a *FAD3-1B* intron 3C.
- SEQ ID NO: 13 sets forth a nucleic acid sequence of a *FAD3-1B* intron 4.
- SEQ ID NO: 14 sets forth a nucleic acid sequence of a *FAD3-1C* intron 4.
- SEQ ID NO: 15 sets forth a nucleic acid sequence of a *FAD2-1A* gene sequence.
- 20       SEQ ID NOs: 16 and 17 set forth nucleic acid sequences of *FAD2-1A* PCR primers.
- SEQ ID NO: 18 sets forth a nucleic acid sequence of a partial *FAD2-1A* genomic clone.
- SEQ ID NO: 19 sets forth a nucleic acid sequence of a partial *FAD2-1B* genomic clone.
- SEQ ID NOs: 20 and 21 set forth nucleic acid sequences of *FAD3-1A* PCR primers.
- SEQ ID NO: 22 sets forth a nucleic acid sequence of a *FAD2-1B* promoter.
- 25       SEQ ID NO: 23 sets forth a nucleic acid sequence of a partial *FAD3-1A* genomic clone.
- SEQ ID NOs: 24 through 39 set forth nucleic acid sequences of PCR primers.

SEQ ID NO: 40 sets forth a nucleic acid sequence of a soybean *FATB* genomic clone.

SEQ ID NO: 41 sets forth a nucleic acid sequence of a soybean *FATB* intron I.

SEQ ID NO: 42 sets forth a nucleic acid sequence of a soybean *FATB* intron II.

SEQ ID NO: 43 sets forth a nucleic acid sequence of a soybean *FATB* intron III.

5 SEQ ID NO: 44 sets forth an amino acid sequence of a soybean *FATB* enzyme.

SEQ ID NO: 45 sets forth a nucleic acid sequence of a soybean *FATB* partial genomic clone.

SEQ ID NOs: 46-53 set forth nucleic acid sequences of oligonucleotide primers.

10 SEQ ID NO: 54 sets forth a nucleic acid sequence of a PCR product containing soybean *FATB* intron II.

SEQ ID NO: 55 sets forth a nucleic acid sequence of a soybean *FATB* cDNA.

#### Definitions

As used herein, the term "gene" is used to refer to a nucleic acid sequence that encompasses a 5' promoter region associated with the expression of the gene product, any  
15 intron and exon regions and 3' untranslated regions associated with the expression of the gene product.

As used herein, a target gene can be any gene of interest present in an organism which contains a transcribed intron. A target gene may be endogenous or introduced.

As used herein, when referring to proteins and nucleic acids herein, the use of plain  
20 capitals, e.g., "FATB", indicates a reference to an enzyme, protein, polypeptide, or peptide, and the use of italicized capitals, e.g., "*FATB*", is used to refer to nucleic acids, including without limitation genes, cDNAs, and mRNAs.

As used herein, a cell or organism can have a family of more than one gene encoding a particular enzyme. As used herein, a gene family is two or more genes in an organism which  
25 encode proteins that exhibit similar functional attributes. An example of two members of a gene family are *FAD2-1* and *FAD2-2*. As used herein, a "*FAD2* gene family member" is any

*FAD2* gene found within the genetic material of the plant. As used herein, a “*FAD3* gene family member” is any *FAD3* gene found within the genetic material of the plant. As used herein, a “*FATB* gene family member” is any *FATB* found within the genetic material of the plant. A gene family can be additionally classified by the similarity of the nucleic acid sequences. In a preferred aspect of this embodiment, a gene family member exhibits at least 60%, more preferably at least 70%, more preferably at least 80% nucleic acid sequence identity in the coding sequence portion of the gene.

As used herein, RNAi and dsRNA both refer to gene-specific silencing that is induced by the introduction of a double-stranded RNA molecule, *see e.g.*, U.S. Patents 6,506,559 and 6,573,099, and U.S. patent applications 09/056,767 and 09/127,735.

As used herein, a “dsRNA molecule” and an “RNAi molecule” both refer to a double-stranded RNA molecule capable, when introduced into a cell or organism, of at least partially reducing the level of an mRNA species present in a cell or a cell of an organism.

As used herein, an “intron dsRNA molecule” and an “intron RNAi molecule” both refer to a double-stranded RNA molecule capable, when introduced into a cell or organism, of at least partially reducing the level of an mRNA species present in a cell or a cell of an organism where the double-stranded RNA molecule exhibits sufficient identity to an intron of a gene present in the cell or organism to reduce the level of an mRNA containing that intron sequence.

As used herein, a “*FAD2*”, “ $\Delta 12$  desaturase” or “omega-6 desaturase” gene is a gene that encodes an enzyme capable of catalyzing the insertion of a double bond into a fatty acyl moiety at the twelfth position counted from the carboxyl terminus.

As used herein, the terminology “*FAD2-1*” is used to refer to a *FAD2* gene that is naturally expressed in a specific manner in seed tissue.

As used herein, the terminology “*FAD2-2*” is used to refer a *FAD2* gene that is (a) a different gene from a *FAD2-1* gene and (b) is naturally expressed in multiple tissues, including the seed.

As used herein, a "*FAD3*", " $\Delta 15$  desaturase" or "omega-3 desaturase" gene is a gene that encodes an enzyme capable of catalyzing the insertion of a double bond into a fatty acyl moiety at the fifteenth position counted from the carboxyl terminus.

As used herein, the terminology "*FAD3-1*" is used to refer a *FAD3* gene that is naturally expressed in multiple tissues, including the seed.

As used herein, the capital letter that follows the gene terminology (A, B, C) is used to designate the family member, i.e., *FAD2-1A* is a different gene family member from *FAD2-1B*.

The term "non-coding" refers to sequences of nucleic acid molecules that do not encode part or all of an expressed protein. Non-coding sequences include but are not limited to introns, promoter regions, 3' untranslated regions, and 5' untranslated regions.

The term "intron" as used herein refers to the normal sense of the term as meaning a segment of nucleic acid molecules, usually DNA, that does not encode part of or all of an expressed protein, and which, in endogenous conditions, is transcribed into RNA molecules, but which is spliced out of the endogenous RNA before the RNA is translated into a protein. The splicing, i.e., intron removal, occurs at a defined splice site, e.g., typically at least about 4 nucleotides, between cDNA and intron sequence. For example, without limitation, the sense and antisense intron segments illustrated herein, which form a double-stranded RNA contained no splice sites.

The term "spliceable intron" as used herein refers to an intron that contains functional splice sites at each end. For example, without limitation, in the constructs illustrated herein, spliceable introns have been used to form the hairpin loop connecting two antiparallel RNA strands of intron sequence which had splice sites removed.

The term "exon" as used herein refers to the normal sense of the term as meaning a segment of nucleic acid molecules, usually DNA, that encodes part of or all of an expressed protein.



As used herein, a promoter that is "operably linked" to one or more nucleic acid sequences is capable of driving expression of one or more nucleic acid sequences, including multiple coding or non-coding nucleic acid sequences arranged in a polycistronic configuration.

5 As used herein, a "series" is a sequential collection of elements arranged consecutively.

#### Nucleic Acid Molecules

Agents of the invention include nucleic acid molecules. In an aspect of the present invention, a nucleic acid molecule comprises a nucleic acid sequence, which when introduced into a cell or organism, is capable of selectively reducing the level of a target protein and/or  
10 transcript that encodes a target protein.

In a preferred aspect, a nucleic acid molecule of the present invention exhibits sufficient homology to one or more introns which when introduced into a cell or organism as a dsRNA construct, is capable of effectively eliminating, substantially reducing, or at least partially reducing the level of an mRNA transcript or protein encoded by the gene from which  
15 the intron was derived. In another preferred aspect, a nucleic acid molecule of the present invention exhibits sufficient homology to one or more introns such that, when introduced into a cell or organism as a dsRNA construct, the nucleic acid molecule is capable of effectively eliminating, substantially reducing, or at least partially reducing the level of an mRNA transcript or protein encoded by a gene family member from which the intron was derived. In  
20 a preferred aspect, a dsRNA construct does not contain exon sequences corresponding to a sufficient part of an exon to be capable of effectively eliminating, substantially reducing, or at least partially reducing the level of an mRNA transcript or protein encoded by a gene from which the exon was derived.

An intron can be any intron from a gene, whether endogenous or introduced. Nucleic  
25 acid sequences of such introns can be derived from a multitude of sources, including, without limitation, databases such as EMBL and Genbank found at [www-ebi.ac.uk/swisprot/](http://www-ebi.ac.uk/swisprot/); [8](http://www-</a></p></div><div data-bbox=)

expasy.ch/; www-embl-heidelberg.de/; and www-ncbi.nlm.nih.gov. Nucleic acid sequences of

such introns can also be derived, without limitation, from sources such as the GENSCAN program found at //genes.mit.edu/GENSCAN.html. In a further embodiment, additional

introns may be obtained by any method by which additional introns may be identified. In a

5 preferred embodiment, additional introns may be obtained by screening a genomic library with

a probe of either known exon or intron sequences. In another preferred embodiment,

additional introns may be obtained by a comparison between genomic sequence and

corresponding cDNA sequence that allows identification of additional introns. In a more

preferred embodiment, additional introns may be obtained by screening a genomic library with

10 a probe of either known exon or intron sequences. The gene may then be cloned and

confirmed and any additional introns may be identified by a comparison between genomic

sequence and cDNA sequence. Additional introns may, for example without limitation, be

amplified by PCR and used in an embodiment of the present invention.

In another preferred embodiment, an intron, such as for example, a soybean intron, may

15 be cloned by alignment to an intron from another organism, such as, for example, *Arabidopsis*.

In this embodiment, the location of an intron in an *Arabidopsis* amino acid sequence, for

example, is identified. An amino acid sequence, from *Arabidopsis* for example, may then be

aligned, with, for example a soybean amino acid sequence, providing a prediction for the

location of additional soybean introns.

20 In a preferred aspect, the target protein is selected from the group consisting of FAD2,

FAD3, and FATB. In another preferred aspect, the target protein is selected from the group of

genes consisting of FAD2-1A, FAD2-1B, FAD2-2B, FAD3-1A, FAD3-1B, FAD3-1C, and

FATB, or in another aspect two or more of said genes. In a preferred aspect, where homology

is present between or among gene family members, at least two target proteins from the same

25 gene family are affected. In a particularly preferred aspect, the target protein is both FAD2-1A

and FAD2-1B. In another particularly preferred aspect, the target protein is both FAD3-1A and FAD3-1C.

Representative sequences for *FAD2-1A*, *FAD2-1B*, *FAD2-2B*, *FAD3-1A*, *FAD3-1B*, *FAD3-1C* introns include, without limitation, those set forth in U.S. Application Serial Number 10/176,149, filed on June 21, 2002; and U.S. Patent Application Serial Number 09/638,508, filed August 11, 2000; and U.S. Provisional Application Serial Number 60/151,224, filed August 26, 1999; and U.S. Provisional Application Serial Number 60/172,128, filed December 17, 1999.

Representative sequences for *FATB* introns include, without limitation, those set forth in the present application at SEQ ID NOs: 41, 42, and 43, as well as those set forth in U.S. Patent Nos. 5,723,761, 5,955,329, 5,955,650, 6,150,512, 6,331,664, and 6,380,462; and International Patent Publication Nos. WO 01/35726, WO 01/36598, and WO 02/15675.

Representative sequences for *FATB* introns also include, without limitation, those set forth in U.S. Provisional Application Serial Number 60/390,185, filed June 21, 2002.

In a preferred aspect, the target protein is encoded by one member of a gene family. In another preferred aspect, the target gene is a member of a gene family. A particularly preferred use of the present invention is where two or more genes within the gene family exhibit similar nucleic acid sequences within a coding region for the target protein but exhibit dissimilar nucleic acid sequences within a transcribed intron region. In this aspect, a first nucleic acid sequence is similar to a second nucleic acid sequence if a dsRNA molecule to the first nucleic acid sequence reduces the level of a protein and/or a transcript which is encoded by the second nucleic acid sequence. Likewise, in this aspect, a first nucleic acid sequence is dissimilar to a second nucleic acid sequence if a dsRNA molecule directed to the first nucleic acid sequence does not reduce the level of a second protein and/or a transcript which is encoded by the second nucleic acid sequence.

In a preferred aspect, the target gene or target protein is a non-viral gene or protein. In another preferred aspect, the target gene or target protein is an endogenous gene or protein. In a further preferred aspect, the intron is an intron located between exons. In another preferred aspect, the intron is an intron that is within a 5' or 3' UTR. In another preferred aspect, the target gene or protein is a non-endogenous gene or protein; for example, the target gene or protein may be found in a plant pest, such as, for example, in a plant nematode.

Further preferred embodiments of the invention are nucleic acid molecules that are at least 85% identical, preferably at least 90% identical, more preferably 95, 97, 98, 99% identical, or most preferably 100% identical over their entire length to an intron.

“Identity,” as is well understood in the art, is a relationship between two or more polypeptide sequences or two or more nucleic acid molecule sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or nucleic acid molecule sequences, as determined by the match between strings of such sequences. “Identity” can be readily calculated by known methods including, but not limited to, those described in Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M. and Griffin, H.G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math, 48:1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available programs.

Computer programs which can be used to determine identity between two sequences include, but are not limited to, GCG (Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984); suite of five BLAST programs, three designed for nucleotide sequences queries

(BLASTN, BLASTX, and TBLASTX) and two designed for protein sequence queries

(BLASTP and TBLASTN) (Coulson, Trends in Biotechnology, 12:76-80 (1994); Birren et al., Genome Analysis, 1:543-559 (1997)). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH, Bethesda, MD

5 20894; Altschul, S., et al., J. Mol. Biol., 215:403-410 (1990)). The well-known Smith Waterman algorithm can also be used to determine identity.

Parameters for polypeptide sequence comparison typically include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Biol.*, 48:443-453 (1970)

Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad.*

10 *Sci. USA*, 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

A program which can be used with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison, Wisconsin. The above parameters along

15 with no penalty for end gap are the default parameters for peptide comparisons.

Parameters for nucleic acid molecule sequence comparison include the following:

Algorithm: Needleman and Wunsch, *J. Mol. Bio.*, 48:443-453 (1970)

Comparison matrix: matches - +10; mismatches = 0

Gap Penalty: 50

20 Gap Length Penalty: 3

As used herein, "% identity" is determined using the above parameters as the default parameters for nucleic acid molecule sequence comparisons and the "gap" program from GCG, version 10.2.

The invention further relates to nucleic acid molecules that hybridize to a plant intron.

25 In particular, the invention relates to nucleic acid molecules that hybridize under stringent conditions to the above-described nucleic acid molecules. As used herein, the terms "stringent

conditions" and "stringent hybridization conditions" mean that hybridization will generally

occur if there is at least 95% and preferably at least 97% identity between the sequences. An example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM

5 sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/  
milliliter denatured, sheared salmon sperm DNA, followed by washing the hybridization  
support in 0.1x SSC at approximately 65°C. Other hybridization and wash conditions are well  
known and are exemplified in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual,  
Second Edition, Cold Spring Harbor, NY (1989), particularly Chapter 11. As used herein, two  
10 nucleic acid molecules are said to be capable of specifically hybridizing to one another if the  
two molecules are capable of forming an anti-parallel, double-stranded nucleic acid structure.

One subset of the nucleic acid molecules of the invention includes fragment nucleic  
acid molecules. For example, fragment nucleic acid molecules may consist of significant  
portion(s) of, or indeed most of, a plant intron. Alternatively, fragments may comprise smaller  
15 oligonucleotides having from about 15 to about 400 contiguous nucleotide residues and more  
preferably, about 15 to about 45 contiguous nucleotide residues, about 20 to about 45  
contiguous nucleotide residues, about 15 to about 30 contiguous nucleotide residues, about 21  
to about 30 contiguous nucleotide residues, about 21 to about 25 contiguous nucleotide  
residues, about 21 to about 24 contiguous nucleotide residues, about 19 to about 25 contiguous  
20 nucleotide residues, or about 21 contiguous nucleotides. In a preferred embodiment, a  
fragment shows 100% identity to the plant intron. In another preferred embodiment, a  
fragment comprises a portion of a larger nucleic acid sequence.

In another aspect, a fragment nucleic acid molecule has a nucleic acid sequence that is  
at least 15, 25, 50, or 100 contiguous nucleotides of a nucleic acid molecule of the present  
25 invention. In a preferred embodiment, a nucleic acid molecule has a nucleic acid sequence that  
is at least 15, 25, 50, or 100 contiguous nucleotides of a plant intron.

In one aspect of the present invention the nucleic acids of the present invention are said to be introduced nucleic acid molecules. A nucleic acid molecule is said to be "introduced" if it is inserted into a cell or organism as a result of human manipulation, no matter how indirect. Examples of introduced nucleic acid molecules include, but are not limited to, nucleic acids that have been introduced into cells via transformation, transfection, injection, and projection, and those that have been introduced into an organism via methods including, but not limited to, conjugation, endocytosis, and phagocytosis. The cell or organism can be, or can be derived from, a plant, plant cell, algae, algae cell, fungus, fungal cell, or bacterial cell. A nucleic acid molecule of the present invention may be stably integrated into a nuclear, chloroplast or mitochondrial genome, preferably into the nuclear genome.

An agent, preferably a dsRNA molecule, is preferably capable of providing at least a partial reduction, more preferably a substantial reduction, or most preferably effective elimination of another agent such as a protein or mRNA.

As used herein, "a reduction" of the level of an agent such as a protein or mRNA means that the level is reduced relative to a cell or organism lacking a dsRNA molecule capable of reducing the agent.

As used herein, "at least a partial reduction" of the level of an agent such as a protein or mRNA means that the level is reduced at least 25% relative to a cell or organism lacking a dsRNA molecule capable of reducing the agent.

As used herein, "a substantial reduction" of the level of an agent such as a protein or mRNA means that the level is reduced relative to a cell or organism lacking a dsRNA molecule capable of reducing the agent, where the reduction of the level of the agent is at least 75%.

As used herein, "an effective elimination" of an agent such as a protein or mRNA is relative to a cell or organism lacking a dsRNA molecule capable of reducing the agent, where the reduction of the level of the agent is greater than 95%.

An agent, preferably a dsRNA molecule, is preferably capable of providing at least a partial reduction, more preferably a substantial reduction, or most preferably effective elimination of another agent such as a protein or mRNA, wherein the agent leaves the level of a second agent essentially unaffected, substantially unaffected, or partially unaffected.

5       As used herein, "essentially unaffected" refers to a level of an agent such as a protein or mRNA transcript that is either not altered by a particular event or altered only to an extent that does not affect the physiological function of that agent. In a preferred aspect, the level of the agent that is essentially unaffected is within 20%, more preferably within 10%, and even more preferably within 5% of the level at which it is found in a cell or organism that lacks a nucleic  
10   acid molecule capable of selectively reducing another agent.

      As used herein, "substantially unaffected" refers to a level of an agent such as a protein or mRNA transcript in which the level of the agent that is substantially unaffected is within 49%, more preferably within 35%, and even more preferably within 24% of the level at which it is found in a cell or organism that lacks a nucleic acid molecule capable of selectively  
15   reducing another agent.

      As used herein, "partially unaffected" refers to a level of an agent such as a protein or mRNA transcript in which the level of the agent that is partially unaffected is within 80%, more preferably within 65%, and even more preferably within 50% of the level at which it is found in a cell or organism that lacks a nucleic acid molecule capable of selectively reducing  
20   another agent.

      When levels of an agent are compared, such a comparison is preferably carried out between organisms with a similar genetic background. In another even more preferable aspect, a similar genetic background is a background where the organisms being compared are plants, and the plants are isogenic except for any genetic material originally introduced using plant  
25   transformation techniques.



In a preferred aspect, the capability of a nucleic acid molecule to reduce or selectively reduce the level of a gene relative to another gene is carried out by a comparison of levels of mRNA transcripts. As used herein, mRNA transcripts include processed and non-processed mRNA transcripts. In another preferred aspect, the capability of a nucleic acid molecule to  
5 reduce or selectively reduce the level of a gene relative to another gene is carried out by a comparison of phenotype. In a preferred aspect, the comparison of phenotype is a comparison of oil composition.

In a further embodiment, a nucleic acid molecule, when introduced into a cell or organism, selectively reducing the level of a protein and/or transcript encoded by a first gene  
10 while leaving the level of a protein and/or transcript encoded by a second gene partially unaffected, substantially unaffected, or essentially unaffected, also alters the oil composition of the cell or organism.

#### Organisms

The constructs of this invention can be used to suppress any gene containing unique  
15 intron sequence of a target gene for suppression in a eukaryotic organism, such as for example without limitation, plants or animals, such as mammals, insects, nematodes, fish, and birds. The target gene for suppression can be an endogenous gene or a transgene in an organism to be transformed with a construct of the present invention. Alternatively, the target gene for suppression can be in a non-transgenic organism which acquires the dsRNA or DNA  
20 producing dsRNA by ingestion or infection by a transgenic organism. *See e.g.*, U.S. Patent 6,506,559.

Thus, an aspect of this invention provides a method where the target gene for suppression encodes a protein in an insect or nematode which is a pest to a plant. In an aspect, a method comprises introducing into the genome of a pest-targeted plant a nucleic acid  
25 construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule which is effective for reducing expression of a target gene within the

pest when the pest, e.g., insect or nematode ingests cells from said plant. In a preferred

embodiment, the gene suppression is fatal to the pest.

#### Plant Constructs and Plant Transformants

Exogenous genetic material may be transferred into a plant cell and the plant cell  
5 regenerated into a whole, fertile or sterile plant or plant part. Exogenous genetic material is  
any genetic material, whether naturally occurring or otherwise, from any source that is capable  
of being inserted into any organism. Such exogenous genetic material includes, without  
limitation, nucleic acid molecules that encode a dsRNA molecule of the present invention.

In a preferred aspect, a plant cell or plant of the present invention includes a nucleic  
10 acid molecule that exhibits sufficient homology to one or more plant introns such that when it  
is expressed as a dsRNA construct, it is capable of effectively eliminating, substantially  
reducing, or at least partially reducing the level of an mRNA transcript or protein encoded by  
the gene from which the intron was derived or any gene which has an intron with homology to  
the target intron.

15 In one embodiment of the invention, the expression level of a protein or transcript in  
one family member of that gene is selectively reduced while leaving the level of a protein or  
transcript of a second family member partially unaffected. In a preferred embodiment of the  
invention, the expression level of a protein or transcript in one family member of that gene is  
selectively reduced while leaving the level of a protein or transcript of a second family member  
20 substantially unaffected. In a highly preferred embodiment of the invention, the expression  
level of a protein or transcript in one family member of that gene is selectively reduced while  
leaving the level of a protein or transcript of a second family member essentially unaffected.

In a particularly preferred embodiment, a transgenic plant includes a nucleic acid  
molecule that comprises a nucleic acid sequence, which is capable of selectively reducing the  
25 expression level of a protein and/or transcript encoded by certain *FAD2* and/or *FAD3* genes

while leaving the level of a protein and/or transcript of at least one other *FAD2* or *FAD3* gene in the plant partially unaffected or more preferably substantially or essentially unaffected.

The levels of target products such as transcripts or proteins may be decreased throughout an organism such as a plant or mammal, or such decrease in target products may be localized in one or more specific organs or tissues of the organism. For example, the levels of products may be decreased in one or more of the tissues and organs of a plant including without limitation: roots, tubers, stems, leaves, stalks, fruit, berries, nuts, bark, pods, seeds and flowers. A preferred organ is a seed.

The present invention provides nucleic acid constructs that encode a dsRNA molecule of the present invention. In a preferred aspect, such constructs comprise at least one sequence that when transcribed is a sense sequence that exhibits sufficient identity to an intron which when expressed in the presence of its complement (antisense) forms a double-stranded RNA molecule capable of at least partially reducing the level of an mRNA containing the intron sequence. In another preferred aspect, such constructs comprise at least one sequence that when transcribed is a sense sequence that exhibits sufficient identity to more than one intron, preferably more than two introns, more preferably more than three introns, which when expressed in the presence of their complements (antisense) forms a double-stranded RNA molecule capable of at least partially reducing the level of all mRNAs containing the intron sequence.

In one aspect, e.g. for suppressing plant genes, the nucleic acid construct comprises a plant promoter and a DNA sequence capable of expressing a first RNA that exhibits identity to a transcribed intron of a plant gene and expressing a second RNA capable of forming a double-stranded RNA molecule with said first RNA. In a preferred aspect, the first RNA exhibits identity to at least two, more preferably at least three or at least four, five or six plant introns. In another preferred aspect, the first RNA and the second RNA are encoded by physically linked nucleic acid sequences.

When physically linked, the nucleic acid sequences which encode the first RNA and the second RNA (the complement of the first RNA) can in a preferred aspect be separated by a sequence (spacer sequence), preferably one that promotes the formation of a dsRNA molecule. Examples of such sequences include those set forth in Wesley et al., supra, and Hamilton et al., Plant J., 15:737-746 (1988) which are capable of forming a hairpin loop between hybridized RNA. In a preferred aspect, the separating sequence is a spliceable intron. Spliceable introns include, but are not limited to, an intron selected from the group consisting of Pdk intron, *FAD3* intron #5, *FAD3* intron #1, *FAD3* intron #3A, *FAD3* intron #3B, *FAD3* intron #3C, *FAD3* intron #4, *FAD3* intron #5, *FAD2* intron #1, *FAD2-2* intron. Preferred spliceable introns include, but are not limited to, an intron selected from the group consisting of *FAD3* intron #1, *FAD3* intron #3A, *FAD3* intron #3B, *FAD3* intron #3C, and *FAD3* intron #5. Other preferred spliceable introns include, but are not limited to, a spliceable intron that is about 0.75 kb to about 1.1 kb in length and is capable of facilitating an RNA hairpin structure. One non-limiting example of a particularly preferred spliceable intron is *FAD3* intron #5.

In a particularly preferred aspect, the construct comprises a nucleic acid where a first RNA exhibits identity to two or more, preferably three or more introns where the introns are selected from the group consisting of *FAD2-1A*, *FAD2-1B*, *FAD2-2B*, *FAD3-1A*, *FAD3-1B*, *FAD3-1C*, and *FATB* introns.

Constructs may be designed, without limitation, in a 7S expression cassette such as the pCGN3892 vector (Figure 1). Particularly preferred constructs include the following pCGN3892 derived constructs: (1) 7S promoter – *FAD2-1A* sense intron – *FAD3-1C* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense intron – spliceable *FAD3* intron #5 – *FAD3-1B* antisense intron – *FAD3-1A* antisense intron – *FAD3-1C* antisense intron – *FAD2-1A* antisense intron – pea *rbcS*; (2) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense intron – spliceable *FAD3* intron #5 – *FAD3-1B* antisense intron – *FAD3-1A* antisense intron – *FAD2-1A* antisense intron – pea *rbcS*; (3) 7S promoter – *FAD2-1A* sense

intron – *FAD3-1A* sense intron – spliceable *FAD3* intron #5 – *FAD3-1A* antisense intron –  
*FAD2-1A* antisense intron – pea *rbcS*; (4) 7S promoter – *FAD2-1A* sense intron – spliceable  
*FAD3* intron #5 – *FAD2-1A* antisense intron – pea *rbcS*; (5) 7S promoter – *FAD3-1A* sense  
intron – spliceable *FAD3* intron #5 – *FAD3-1A* antisense intron – pea *rbcS*; (6) 7S promoter –  
5 *FAD2-1A* sense intron – *FAD3-1A* sense 3'UTR – spliceable *FAD3* intron #5 – *FAD3-1A*  
antisense 3'UTR – *FAD2-1A* antisense intron – pea *rbcS*; and (7) 7S promoter – *FAD2-1A*  
sense intron – *FAD3-1A* sense 3'UTR – *FAD3-1B* sense 3'UTR – spliceable *FAD3* intron #5 –  
*FAD3-1B* antisense 3'UTR – *FAD3-1A* antisense 3'UTR – *FAD2-1A* antisense intron – pea  
*rbcS*.

10 Other preferred constructs may be prepared using one or more *FATB* introns in a 7S  
expression cassette such as the pCGN3892 vector (Figure 1). For example, other particularly  
preferred constructs include without limitation the following pCGN3892 derived constructs:  
(1) 7S promoter – *FATB* sense intron I – *FATB* sense intron II – spliceable *FAD3* intron #5 –  
*FATB* antisense intron II – *FATB* antisense intron I – pea *rbcS*; (2) 7S promoter – *FATB* sense  
15 intron II – *FATB* sense intron I – spliceable *FAD3* intron #5 – *FATB* antisense intron I – *FATB*  
antisense intron II – pea *rbcS*; (3) 7S promoter – *FATB* sense intron – spliceable *FAD3* intron  
#5 – *FATB* antisense intron – pea *rbcS*.

In another embodiment of the present invention, a construct lacking a promoter and a 3'  
flanking region may be injected directly into either the cytoplasm, or preferably into the  
20 nucleus, of a cell via microinjection.

Transgenic DNA constructs used for transforming plant cells for intron-based RNAi  
will comprise the heterologous DNA which encodes the double-stranded RNA and a promoter  
to express the heterologous DNA in the host plant cells. As is well known in the art, such  
constructs typically also comprise a promoter and other regulatory elements, 3' untranslated  
25 regions (such as polyadenylation sites), transit or signal peptides and marker genes elements as  
desired. For instance, see U.S. Patent Nos. 5,858,642 and 5,322,938 which disclose versions

of the constitutive promoter derived from cauliflower mosaic virus (CaMV35S), U.S. Patent

6,437,217 which discloses a maize RS81 promoter, U.S. Patent 5,641,876 which discloses a

rice actin promoter, U.S. Patent 6,426,446 which discloses a maize RS324 promoter, U.S.

Patent 6,429,362 which discloses a maize PR-1 promoter, U.S. Patent 6,232,526 which

5 discloses a maize A3 promoter, U.S. Patent 6,177,611 which discloses constitutive maize

promoters, U.S. Patent 6,433,252 which discloses a maize L3 oleosin promoter, U.S. Patent

6,429,357 which discloses a rice actin 2 promoter and intron, U.S. Patent 5,837,848 which

discloses a root specific promoter, U.S. Patent 6,084,089 which discloses cold-inducible

promoters, U.S. Patent 6,294,714 which discloses light-inducible promoters, U.S. Patent

10 6,140,078 which discloses salt-inducible promoters, U.S. Patent 6,252,138 which discloses

pathogen-inducible promoters, U.S. Patent 6,175,060 which discloses phosphorus deficiency-

inducible promoters, U.S. Patent Application Publication 2002/0192813A1 which discloses 5',

3' and intron elements useful in the design of effective plant expression vectors, U.S. Patent

Application No. 09/078,972 which discloses a coixin promoter, U.S. Patent Application No.

15 09/757,089 which discloses a maize chloroplast aldolase promoter.

Constructs or vectors may also include, with the region of interest, a nucleic acid sequence that acts, in whole or in part, to terminate transcription of that region. A number of such sequences have been isolated, including the Tr7 3' sequence and the NOS 3' sequence (Ingelbrecht et al., The Plant Cell 1:671-680 (1989); Bevan et al., Nucleic Acids Res. 11:369-

20 385 (1983)). Regulatory transcript termination regions can be provided in plant expression

constructs of this invention as well. Transcript termination regions can be provided by the

DNA sequence encoding the gene of interest or a convenient transcription termination region

derived from a different gene source, for example, the transcript termination region that is

naturally associated with the transcript initiation region. The skilled artisan will recognize that

25 any convenient transcript termination region that is capable of terminating transcription in a

plant cell can be employed in the constructs of the present invention.

A vector or construct may also include regulatory elements. Examples of such include the Adh intron 1 (Callis et al., Genes and Develop. 1:1183-1200 (1987)), the sucrose synthase intron (Vasil et al., Plant Physiol. 91:1575-1579 (1989)) and the TMV omega element (Gallie et al., The Plant Cell 1:301-311 (1989)). These and other regulatory elements may be included  
5 when appropriate.

In practice DNA is introduced into only a small percentage of target cells in any one experiment. Marker genes are used to provide an efficient system for identification of those cells that are stably transformed by receiving and integrating a transgenic DNA construct into their genomes. Preferred marker genes provide selective markers which confer resistance to a  
10 selective agent, such as an antibiotic or herbicide. Potentially transformed cells are exposed to the selective agent. In the population of surviving cells will be those cells where, generally, the resistance-conferring gene has been integrated and expressed at sufficient levels to permit cell survival. Cells may be tested further to confirm stable integration of exogenous DNA.

Useful selective marker genes include those conferring resistance to antibiotics such as

15 kanamycin (nptII), hygromycin B (aph IV) and gentamycin (aac3 and aacC4) or resistance to herbicides such as glufosinate (bar or pat) and glyphosate (EPSPS). Examples of such selectable markers are illustrated in U.S. Patents 5,550,318; 5,633,435; 5,780,708 and 6,118,047. Screenable markers which provide an ability to visually identify transformants can also be employed, e.g., a gene expressing a colored or fluorescent protein such as a luciferase  
20 or green fluorescent protein (GFP) or a gene expressing a beta-glucuronidase or uidA gene (GUS) for which various chromogenic substrates are known.

#### Transformation Methods and Transgenic Plants

Methods and compositions for transforming plants by introducing a transgenic DNA construct or a nucleic acid molecule of the present invention into a plant genome in the practice  
25 of this invention can include any of the well-known and demonstrated methods. Preferred methods of plant transformation are microprojectile bombardment as illustrated in U.S. Patents

5,015,580; 5,550,318; 5,538,880; 6,160,208; 6,399,861 and 6,403,865 and *Agrobacterium*-

mediated transformation as illustrated in U.S. Patents 5,635,055; 5,824,877; 5,591,616;

5,981,840 and 6,384,301. See also U.S. Patent Application No. 09/823,676 for a description of

vectors, transformation methods, and production of transformed *Arabidopsis thaliana* plants

5 where transcription factors such as G1073 are constitutively expressed by a CaMV35S promoter.

Transformation methods of this invention to provide plants with enhanced environmental stress tolerance are preferably practiced in tissue culture on media and in a controlled environment. "Media" refers to the numerous nutrient mixtures that are used to  
10 grow cells in vitro, that is, outside of the intact living organism. Recipient cell targets include, but are not limited to, meristem cells, Type I, Type II, and Type III callus, immature embryos and gametic cells such as microspores, pollen, sperm and egg cells. It is contemplated that any cell from which a fertile plant may be regenerated is useful as a recipient cell. Callus may be initiated from tissue sources including, but not limited to, immature embryos, seedling apical  
15 meristems, microspores and the like. Those cells, which are capable of proliferating as calli, also are recipient cells for genetic transformation. Practical transformation methods and materials for making transgenic plants of this invention, e.g. various media and recipient target cells, transformation of immature embryos and subsequent regeneration of fertile transgenic plants are disclosed in U.S. Patent 6,194,636 and U.S. Patent Application No. 09/757,089.

20 Examples of species that have been transformed by microprojectile bombardment include monocot species such as maize (PCT Publication WO 95/06128), barley, wheat (U.S. Patent No. 5,563,055), rice, oat, rye, sugarcane, and sorghum; as well as a number of dicots including tobacco, soybean (U.S. Patent No. 5,322,783), sunflower, peanut, cotton, tomato, and legumes in general (U.S. Patent No. 5,563,055).

25 The regeneration, development, and cultivation of plants from various transformed explants is well documented in the art. This regeneration and growth process typically



includes the steps of selecting transformed cells and culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage.

Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil. Cells that survive the exposure to the selective agent, or cells that have been scored positive in a screening assay, may be cultured in media that supports regeneration of plants. Developing plantlets are transferred to soil less plant growth mix, and hardened off, prior to transfer to a greenhouse or growth chamber for maturation.

The present invention can be used with any transformable cell or tissue. Those of skill in the art recognize that a number of plant cells or tissues are transformable in which after insertion of exogenous DNA and appropriate culture conditions the plant cells or tissues can form into a differentiated plant. Tissue suitable for these purposes can include but is not limited to immature embryos, scutellar tissue, suspension cell cultures, immature inflorescence, shoot meristem, nodal explants, callus tissue, hypocotyl tissue, cotyledons, roots, and leaves.

Any suitable plant culture medium can be used. Examples of suitable media would include but are not limited to MS-based media (Murashige and Skoog, *Physiol. Plant*, 15:473-497, (1962) or N6-based media (Chu et al., *Scientia Sinica* 18:659, (1975) supplemented with additional plant growth regulators including but not limited to auxins, cytokinins, ABA, and gibberellins. Those of skill in the art are familiar with the variety of tissue culture media, which when supplemented appropriately, support plant tissue growth and development and are suitable for plant transformation and regeneration. These tissue culture media can either be purchased as a commercial preparation, or custom prepared and modified. Those of skill in the art are aware that media and media supplements such as nutrients and growth regulators for use in transformation and regeneration and other culture conditions such as light intensity during incubation, pH, and incubation temperatures can be optimized for the particular variety of interest.

Any of the nucleic acid molecules of the invention may be introduced into a plant cell in a permanent or transient manner in combination with other genetic elements, for example, including but not limited to, vectors, promoters, and enhancers. Further, any of the nucleic acid molecules of the invention may be introduced into a plant cell in a manner that allows for expression or overexpression of the protein or fragment thereof encoded by the nucleic acid molecule.

It is understood that two or more nucleic molecules of the present invention may be introduced into a plant using a single construct and that construct can contain more than one promoter. In embodiments where the construct is designed to express two nucleic acid molecules, it is preferred that the two promoters are (i) two constitutive promoters, (ii) two seed-specific promoters, or (iii) one constitutive promoter and one seed-specific promoter. Preferred seed-specific and constitutive promoters are a napin and a 7S promoter, respectively. It is understood that two or more of the nucleic molecules may be physically linked and expressed utilizing a single promoter, preferably a seed-specific or constitutive promoter.

It is further understood that two or more nucleic acids of the present invention may be introduced into a plant using two or more different constructs. Alternatively, two or more nucleic acids of the present invention may be introduced into two different plants and the plants may be crossed to generate a single plant expressing two or more nucleic acids. In an RNAi embodiment, it is understood that the sense and antisense strands may be introduced into the same plant on one construct or two constructs. Alternatively, the sense and antisense strands may be introduced into two different plants and the plants may be crossed to generate a single plant expressing both sense and antisense strands.

The present invention also provides for parts of the plants, particularly reproductive or storage parts. Plant parts, without limitation, include seed, endosperm, ovule, pollen, roots, tubers, stems, leaves, stalks, fruit, berries, nuts, bark, pods, seeds and flowers. In a particularly preferred embodiment of the present invention, the plant part is a seed.

The present invention also provides a container of over 10,000, more preferably 20,000, and even more preferably 40,000 seeds where over 10%, more preferably 25%, more preferably 50% and even more preferably 75% or 90% of the seeds are seeds derived from a plant of the present invention.

5       The present invention also provides a container of over 10 kg, more preferably 25 kg, and even more preferably 50 kg seeds where over 10%, more preferably 25%, more preferably 50% and even more preferably 75% or 90% of the seeds are seeds derived from a plant of the present invention.

Plants of the present invention can be part of or generated from a breeding program.

10       The choice of breeding method depends on the mode of plant reproduction, the heritability of the trait or traits being improved, and the type of cultivar used commercially (e.g.,  $F_1$  hybrid cultivar, pureline cultivar, etc). Selected, non-limiting approaches, for breeding the plants of the present invention are set forth below. A breeding program can be enhanced using marker-assisted selection of the progeny of any cross. It is further understood that any commercial and  
15       non-commercial cultivars can be utilized in a breeding program. Factors such as, for example, emergence vigor, vegetative vigor, stress tolerance, disease resistance, branching, flowering, seed set, seed size, seed density, standability, and threshability will generally dictate the choice.

For highly heritable traits, a choice of superior individual plants evaluated at a single  
20       location will be effective, whereas for traits with low heritability, selection should be based on mean values obtained from replicated evaluations of families of related plants. Popular selection methods commonly include pedigree selection, modified pedigree selection, mass selection, and recurrent selection. In a preferred embodiment, a backcross or recurrent breeding program is undertaken.

25       The complexity of inheritance influences choice of the breeding method. Backcross breeding can be used to transfer one or a few favorable genes for a highly heritable trait into a

desirable cultivar. This approach has been used extensively for breeding disease-resistant cultivars. Various recurrent selection techniques are used to improve quantitatively inherited traits controlled by numerous genes. The use of recurrent selection in self-pollinating crops depends on the ease of pollination, the frequency of successful hybrids from each pollination, and the number of hybrid offspring from each successful cross.

Breeding lines can be tested and compared to appropriate standards in environments representative of the commercial target area(s) for two or more generations. The best lines are candidates for new commercial cultivars; those still deficient in traits may be used as parents to produce new populations for further selection.

One method of identifying a superior plant is to observe its performance relative to other experimental plants and to a widely grown standard cultivar. If a single observation is inconclusive, replicated observations can provide a better estimate of genetic worth. A breeder can select and cross two or more parental lines, followed by repeated selfing and selection, producing many new genetic combinations.

The development of new cultivars requires the development and selection of varieties, the crossing of these varieties and the selection of superior hybrid crosses. The hybrid seed can be produced by manual crosses between selected male-fertile parents or by using male sterility systems. Hybrids are selected for certain single gene traits such as pod color, flower color, seed yield, pubescence color, or herbicide resistance, which indicate that the seed is truly a hybrid. Additional data on parental lines, as well as the phenotype of the hybrid, influence a breeder's decision whether to continue with the specific hybrid cross.

Agents of the present invention can be utilized in a variety of methods. For example, the present invention provides a method of altering the expression of a target gene comprising (a) introducing into a cell a first DNA sequence capable of expressing a first RNA which exhibits identity to a transcribed intron of the target gene and a second DNA sequence and a method of modifying a level of a target protein comprising: (a) growing a plant having

integrated into a genome a nucleic acid molecule comprising a first DNA sequence which encodes a first RNA that exhibits identity to a transcribed intron of an mRNA that encodes the target protein and a second DNA sequence capable of expressing a second RNA capable of forming a double-stranded RNA molecule with the first RNA and (b) expressing the first and second RNA. In a preferred aspect, the expression of a target gene is altered or modified if the level of an mRNA or protein encoded by that gene is altered, in a more preferred aspect, a method of the present invention provides for at least a partial reduction, or more preferably a substantial reduction or effective elimination of an encoded agent such as a protein or mRNA.

The following examples are illustrative and not intended to be limiting in any way.

## EXAMPLES

**Example 1-** This example illustrates the identification of introns which are useful for demonstrating the suppression of genes using intron double-stranded RNA molecules.

### *1A. Soybean $\Delta 12$ Desaturase (*FAD2-1*)*

A soybean *FAD2-1A* sequence is identified by screening a soybean genomic library using a soybean *FAD2-1* cDNA probe. Three putative soy *FAD2-1* clones are identified and plaque purified. Two of the three soy *FAD2-1* clones are ligated into pBluescript II KS+ (Stratagene) and sequenced. Both clones (14-1 and 11-12) are the same and match the soy *FAD2-1* cDNA exactly. A sequence of the entire *FAD2-1A* clone is provided in SEQ ID NO:15.

Prior to obtaining a full length clone, a portion of the *FAD2-1A* genomic clone is PCR amplified using PCR primers designed from the 5' untranslated sequence (Primer 12506, 5'-ATACAA GCCACTAGGCAT-3', SEQ ID NO:16) and within the cDNA (Primer 11698: 5'-GATTGGCCATGCAATGAGGGAAAAGG-3', SEQ ID NO:17). The resulting PCR product is cloned into the vector pCR 2.1 (Invitrogen) and sequenced. A soy *FAD2-1A* partial genomic clone (SEQ ID NO:18) with an intron region (SEQ ID NO:1) is identified by comparison to the

soybean cDNA sequence using the Pustell comparison program in Macvector. The *FAD2-1A* intron #1 sequence (SEQ ID NO:1) begins after the ATG start codon, and is 420 bases long.

A second *FAD2-1* gene family member is also identified and cloned, and is referred to herein as *FAD2-1B*. The soy *FAD2-1B* partial genomic clone (SEQ ID NO:19) has a coding  
5 region (base pairs 1783-1785 and 2191-2463) and an intron region (base pairs 1786-2190)  
which are identified by comparison to the soybean cDNA sequence using the Pustell  
comparison program in Macvector. The *FAD2-1B* intron #1 sequence (SEQ ID NO:2) begins  
after the ATG start codon and is 405 bases long. Other regions in the *FAD2-1B* partial  
genomic clone (SEQ ID NO: 19) include a promoter (base pairs 1-1704) (SEQ ID NO: 22) and  
10 5'UTR (base pairs 1705-1782).

*1B. Soybean  $\Delta 15$  Desaturase (FAD3)*

A partial soybean *FAD3-1A* genomic sequence is PCR amplified from soybean DNA  
using primers 10632, 5'-CUACUACUACUACTCGAGACAAAGCCTTTAGCCTATG-3'  
(SEQ ID NO: 20), and 10633: 5'-

15 CAUCAUCAUGGATCCCATGTCTCTCTATGCAAG-3' (SEQ ID NO: 21). The  
Expand Long Template PCR system (Roche Applied Sciences, Indianapolis) is used according  
to the manufacturer's directions. The resulting PCR products are cloned into the vector pCR  
2.1 (Invitrogen) and sequenced. A soy *FAD3-1A* partial genomic clone sequence (SEQ ID  
NO: 23) and intron regions are confirmed by comparisons to the soybean *FAD3-1A* cDNA  
20 sequence using the Pustell program in Macvector.

From the identified partial genomic soybean *FAD3-1A* sequence (SEQ ID NO:23),  
seven introns are identified: *FAD3-1A* intron #1(SEQ ID NO:5), *FAD3-1A* intron #2 (SEQ ID  
NO:6 ), *FAD3-1A* intron #3A (SEQ ID NO:7), *FAD3-1A* intron #4 (SEQ ID NO:8), *FAD3-1A*  
intron #5 (SEQ ID NO:9), *FAD3-1A* intron #3B (SEQ ID NO:10), and *FAD3-1A* intron #3C  
25 (SEQ ID NO:11). *FAD3-1A* intron #1 is 191 base pairs long and is located between positions  
294 and 484, *FAD3-1A* intron #2 is 346 base pairs long and is located between positions 577

and 922, *FAD3-1A* intron #3A is 142 base pairs long and is located between positions 991 and 1132, *FAD3-1A* intron #3B is 98 base pairs long and is located between positions 1224 and 1321, *FAD3-1A* intron #3C is 115 base pairs long and is located between positions 1509 and 1623, *FAD3-1A* intron #4 is 1228 base pairs long and is located between positions 1707 and 2934, and *FAD3-1A* intron #5 is 625 base pairs long and is located between positions 3075 and 3699.

Introns #3C and #4 are also PCR amplified from a second *FAD3* gene family member (*FAD3-1B*). Soybean *FAD3-1B* introns #3C and #4 are PCR amplified from soybean DNA using the following primers, 5' CATGCTTTCTGTGCTTCTC 3' (SEQ ID NO: 26) and 5' GTTGATCCAACCATAGTCG 3' (SEQ ID NO: 27). The PCR products are cloned into the vector pCR 2.1 (Invitrogen) and sequenced. Sequences for the *FAD3-1B* introns #3C and #4 are provided in SEQ ID NOs:12 and 13, respectively.

#### 1C. *FATB* Thioesterase

A soybean *FATB* sequence is identified by screening a soybean genomic library using a soybean *FATB* cDNA probe (SEQ ID NO: 55). Leaf tissue is obtained from Asgrow soy variety A3244, ground up in liquid nitrogen and stored at -80°C until use. 6 ml of SDS Extraction buffer (650 ml sterile ddH<sub>2</sub>O, 100 ml 1M Tris-Cl pH 8, 100 ml 0.25M EDTA, 50 ml 20% SDS, 100 ml 5M NaCl, 4 µl beta-mercaptoethanol) is added to samples of 2 ml frozen/ground leaf tissue, and the mixture is incubated at 65°C for 45 min. The samples are shaken every 15 min. 2 ml ice-cold 5M potassium acetate is added to each sample, the samples are shaken, and then incubated on ice for 20 min. 3 ml CHCl<sub>3</sub> is added to each sample, and then the samples are shaken for 10 min.

The samples are then centrifuged at 10,000 rpm for 20 min, and the protocol is continued with the supernatant. 2 ml isopropanol is added to each sample and mixed. The samples are then centrifuged at 10,000 rpm for 20 min, and the supernatant is drained. The

pellet is resuspended in 200 µl RNase, and incubated at 65°C for 20 minutes. 300 µl

ammonium acetate/isopropanol (1:7) is added, and mixed. The samples are then centrifuged at 10,000 rpm for 15 minutes, and the supernatant is discarded. The pellet is rinsed with 500 µl 80% ethanol, and allowed to air dry. The pellet is then resuspended in 200 µl T10E1 (10mM

5 Tris:1mM EDTA). Approximately 840 µg of clean gDNA is obtained.

Based on the *FATB* cDNA sequence and restriction enzyme patterns, six oligonucleotides are synthesized: F1 (SEQ ID NO: 46), F2 (SEQ ID NO: 47), F3 (SEQ ID NO: 48), R1 (SEQ ID NO: 49), R2 (SEQ ID NO: 50), and R3 (SEQ ID NO: 51). The oligonucleotide are used in pairs for PCR amplification of the isolated soy genomic DNA: pair 10 1 (F1 + R1), pair 2 (F1 + R2), pair 3 (F1 + R3), pair 4 (F2 + R1), pair 5 (F2 + R2), pair 6 (F2 + R3), pair 7 (F3 + R1), and pair 8 (F3 + R2). The PCR amplification is carried out as follows: 1 cycle, 95°C for 10 min; 40 cycles, 95°C for 1 min, 58°C for 30 sec, 72°C for 55 sec; 1 cycle, 72°C for 7 min. Three positive fragments are obtained, specifically from primer pairs 3, 6, and 7. Each fragment is cloned into vector pCR2.1 (Invitrogen). Cloning is successful for 15 fragment #3, which is confirmed and sequenced (SEQ ID NO: 45).

Three introns are identified in the soybean *FATB* gene by comparison of the genomic sequence to the cDNA sequence: intron I (SEQ ID NO: 41) spans base 106 to base 214 of the genomic sequence (SEQ ID NO: 45) and is 109 bp in length; intron II (SEQ ID NO: 42) spans base 289 to base 1125 of the genomic sequence (SEQ ID NO: 45) and is 837 bp in length; and 20 intron III (SEQ ID NO: 43) spans base 1635 to base 1803 of the genomic sequence (SEQ ID NO: 45) and is 169 bp in length.

**Example 2** – This example illustrates constructs for expressing double-stranded RNA using separate promoters for the sense and antisense introns.

25 The *FAD2-1A* intron #1 sequence (SEQ ID NO: 1) is amplified via PCR using the *FAD2-1A* partial genomic clone (SEQ ID NO: 18) as a template and primers 12701 (5'-



ACGAATTCCTCGAGGTAAA TTAAATTGTGCCTGC-3' (SEQ ID NO: 24)) and 12702

(5'-GCGAGATCTATCG ATCTGTGTCAAAGTATAAAC-3' (SEQ ID NO: 25)). The resulting amplification products are cloned into the vector pCR 2.1 (Invitrogen) and sequenced. The *FAD2-1A* intron is then cloned into the expression cassette, pCGN3892 (Figure 1), in sense and antisense orientations. The vector pCGN3892 contains the soybean 7S alpha' promoter and a pea *rbcS* 3'. Both gene fusions are then separately ligated in two sequential steps into pCGN9372, a vector that contains the CP4 gene regulated by the FMV promoter. The resulting vector, which contains the *FAD2-1A* intron in the sense and antisense orientation driven by two separate 7S alpha' promoters and the FMV-CP4 gene selectable marker, is transformed into soybean via *Agrobacterium tumefaciens* strain ABI using methods generally described by Martinell in U.S. Patent No. 6,384,310 to provide transgenic soybean plants with the *FAD2* gene suppressed.

Four of the seven introns identified from the soybean *FAD3-1A* genomic clone are PCR amplified using the *FAD3-1A* partial genomic clone as template and primers as follows: *FAD3-1A* intron #1, primers 12568: 5'-GATCGATGCCCCGGGGTAATAATTTTGTGT-3' (SEQ ID NO: 30) and 12569: 5'-CACGCCTCGAGTGTTCAATTCAATCAATG-3' (SEQ ID NO: 31); *FAD3-1A* intron #2, primers 12514: 5'-CACTCGAGTTAGTTCATACTGGCT-3' (SEQ ID NO: 32) and 12515: 5'-CGCATCGATTGCAAAATCCATCAAA-3' (SEQ ID NO: 33); *FAD3-1A* intron #4, primers 10926: 5'-CUACUACUACUACTCGAGCGTAAATAGTGGGTGAACAC-3' (SEQ ID NO: 34) and 10927: 5'-CAUCAUCAUCAUCTCGAGGAATTCGTCCATTTTAGTACACC-3' (SEQ ID NO: 35); *FAD3-1A* intron #5, primers 10928: 5'-CUACUACUACUACTCGAGGCGCGTACATTTTATTGCTTA-3' (SEQ ID NO: 36) and 10929: 5'-CAUCAUCAUCAUCTCGAGGAATTCTGCAGTGAATCCAAATG-3' (SEQ ID NO: 37). The resulting PCR products for each intron are cloned into the vector pCR 2.1 (Invitrogen) and sequenced.

*FAD3-1A* introns #1, #2, #4 and #5 are all ligated separately into the pCGN3892, in

sense and antisense orientations. pCGN3892 (Figure 1) contains the soybean 7S alpha'

promoter and a pea rbcS 3'. These fusions are ligated in two sequential steps into pCGN9372,

a vector that contains the CP4 gene regulated by the FMV promoter for transformation into

5 soybean. The resulting vectors contain a sense and antisense copy of each intron driven by two

separate 7S alpha' promoters. For example, one such vector contains the *FAD3-1A* intron #1 in

the sense and antisense orientation driven by two separate 7S alpha' promoters and the FMV-

CP4 gene selectable marker. A second example contains the *FAD3-1A* intron #4 in the sense

and antisense orientation driven by two separate 7S alpha' promoters and the FMV-CP4 gene

10 selectable marker. Vectors containing such sense and antisense constructs are transformed into

soybean via *Agrobacterium tumefaciens* strain ABI using methods generally described by

Martinell in U.S. Patent No. 6,384,310.

**Example 3** – This example illustrates constructs for expressing double-stranded RNA using separate promoters for the sense and antisense introns.

15 The soybean *FATB* intron II sequence (SEQ ID NO: 42) is amplified via PCR using the

*FATB* fragment #3 partial genomic clone (SEQ ID NO: 45) as a template and primers 18133

(SEQ ID NO: 52) and 18134 (SEQ ID NO: 53). PCR amplification is carried out as follows: 1

cycle, 95°C for 10 min; 25 cycles, 95°C for 30 sec, 62°C for 30 sec, 72°C for 30 sec; 1 cycle,

72°C for 7 min.

20 PCR amplification results in a product (SEQ ID NO: 54) that is 854 bp long, including

reengineered restriction sites at both ends. The *FATB* intron #2 PCR product is cloned

separately in two sequential steps directly into the expression cassette pCGN3892 (Figure 1) in

a sense or antisense orientation. Vector pCGN3892 contains the soybean 7S alpha' promoter

and a pea RBCS 3'. The resulting vector contains a sense and antisense copy of the *FATB*

25 intron #2, each of which is driven by a separate 7S alpha' promoter. The resulting gene

expression construct, is used for transformation of soybean using *Agrobacterium* methods as described herein.

**Example 4** – The following sixteen steps illustrate the construction of a vector pMON68546 designed for plant transformation to suppress *FAD2*, *FAD3*, and *FATB* genes in soybean. In particular, the construct comprises a 7S alpha promoter operably linked to a series of soybean sense-oriented introns, i.e., a *FAD2-1A* intron #1, a *FAD3-1A* intron #4, a *FATB* intron #2, a *FAD3-1B* intron #4, a hairpin loop-forming spliceable intron, and a complementary series of soybean anti-sense-oriented introns, i.e., a *FAD3-1B* intron #4, a *FATB* intron #2, a *FAD3-1A* intron #4 and a *FAD2-1A* intron #1.

**Step1** - The soybean *FAD3-1A* intron #5, which serves as the spliceable intron portion of the RNAi construct, is PCR amplified using Soy genomic DNA as template, with the following primers:

5' primer = 19037 =

ACTAGTATATTGAGCTCATATTCCACTGCAGTGGATATTGTTTAAACATAGCTAGC  
ATATTACGCGTATATTATACAAGCTTATATTCCCGGGATATTGTCTGACATATTAGC  
GGTACATTTTATTGCTTATTAC

3' primer = 19045 =

ACTAGTATATTGAGCTCATATTCCTGCAGGATATTCTCGAGATATTCACGGTAGTA  
ATCTCCAAGAACTGGTTTTGCTGCTTGTGTCTGCAGTGAATC. These primers add

cloning sites to the 5' and 3' ends. To 5' end: SpeI, SacI, BstXI, PmeI, NheI, MluI, HindIII, XmaI, SmaI, SalI. To 3' end: SpeI, SacI, Sse8387I, XhoI. The Soy *FAD3-1A* intron #5 PCR product is cloned into PCR2.1, resulting in KAWHIT03.0065.

**Step 2** – The soybean *FAD3-1A* intron #5 PCR product is then cloned into an empty AMP vector by digesting KAWHIT03.0065 (Soybean *FAD3-1A* intron #5 in pCR2.1) with SpeI and then the ends are filled in using the Klenow fragment of T4 Polymerase.

pMON68526 (empty AMP vector) is digested with HindIII and then the ends are filled in using

the Klenow fragment of T4 Polymerase. The soybean *FAD3-1A* PCR product with the restriction sites described above is blunt-end ligated into pMON68526, resulting in pMON68541 (*FAD3-1A* PCR product in empty AMP vector).

Step 3 - The soybean *FAD 2-1A* intron #1 is PCR amplified using soybean genomic

5 DNA as template, with the following primers:

5' primer = 18663 = GGGCCCCGGTAAATTAAATTGTGC (Adding Bsp120I site to 5' end);

3' primer = 18664 = CTGTGTCAAAGTATAACAAGTTCAG.

The resulting PCR product is cloned into PCR 2.1 creating KAWHIT03.0038.

10 Step 4 - Soybean *FAD 2-1A* intron #1 PCR product in KAWHIT03.0038 is cloned into KAWHIT03.0032 (empty CM resistant vector with a multiple cloning site) using the restriction sites Bsp120I and EcoRI. The resulting plasmid is KAWHIT03.0039 (Soybean *FAD 2-1A* intron #1 in empty CM resistant vector).

Step 5 - KAWHIT03.0039 is digested with AscI and HindIII and pMON68541 (*FAD3-1A* PCR product in empty AMP vector) is digested with MluI and HindIII. The Soybean *FAD 2-1A* intron #1 is then directionally cloned into pMON68541 to generate KAWHIT03.0071 (soybean *FAD2-1A* intron #1 with soybean *FAD3-1A* Intron #5).

Step 6 - 5' and 3' end portions of soybean *FAD3-1A* intron #4 are PCR amplified to create a 376bp fragment using genomic DNA as template and the following primers:

20 5' Primer of 5' end = 19034 = GGGCCCAAATAGTGGGTGAAC (This primer added a Bsp120I site to 5' end)

3' Primer of 5' end = 18993 = GAACTAAGGGACACAAC

5' Primer of 3' end = 18990 = CTTAGTTCGCTCTTACCTGTGATC

3' Primer of 3' end = 18996 = GTCCATTTTAGTACACCAC

The resulting PCR product is cloned into PCR 2.1 to form KAWHIT03.0067 containing the 5' and 3' ends of intron #4 from the soybean *FAD3-1A*.

Step 7 - KAWHIT03.0067 is cloned into KAWHIT03.0032 (empty CM resistant vector with a multiple cloning site) using the restriction sites Bsp120I and EcoRI, resulting in plasmid  
5 KAWHIT03.0068.

Step 8 - KAWHIT03.0068 (5' and 3' ends of intron #4 from the soybean *FAD3-1A* in CM resistant Vector) is digested with AscI and HindIII and KAWHIT03.0071 (Soybean *FAD2-1A* intron #1 with soybean *FAD3-1A* intron #5) is digested with MluI and HindIII. The 5' and 3' ends of intron #4 from the soybean *FAD3-1A* are directionally ligated into  
10 KAWHIT03.0071 creating KAWHIT03.0075 (soybean *FAD2-1A* intron#1, soybean *FAD3-1A* intron #4 ends and soybean *FAD3-1A* intron #5).

Step 9 - 5' and 3' end portions of soybean *FATB* intron #2 are PCR amplified to create a 374bp fragment using genomic DNA as template and the following primers:

15 5' Primer of 5' end = 19205 = GGGCCCTTCTCGATTCTTTTCTC (Adding Bsp120I site to 5' end)

3' Primer of 5' end = 19147 = CAGACAAGGCAAAGAAACAAGGGAG

5' Primer of 3' end = 19088 = GCCTTGTCTGGTCCGATTGATTTCTCG

3' Primer of 3' end = 19089 = CATGCATGCAAAATATACGCAAGTTAG

The resulting PCR product is cloned into PCR 2.1 to form KAWHIT03.0069.

20 Step 10 - KAWHIT03.0069 (containing the 5' and 3' ends of Intron #2 from the soybean *FATB*) is cloned into KAWHIT03.0032 (empty CM resistant vector with a multiple cloning site) using the restriction sites Bsp120I and EcoRI to create KAWHIT03.0070. (5' and 3' ends of intron #2 from the soybean *FATB* in CM resistant vector).

Step 11 - KAWHIT03.0070 (5' and 3' ends of intron #2 from the soybean *FATB* in CM  
25 resistant vector) is digested with AscI and HindIII and KAWHIT03.0075 (Soybean *FAD2-1A*

intron #1, soybean *FAD3-1A* intron #4 ends and soybean *FAD3-1A* intron #5) is digested with MluI and HindIII. The 5' and 3' ends of intron #2 from the soybean *FATB* are directionally ligated into KAWHIT03.0075 to generate KAWHIT03.0077 (Soybean *FAD2-1A* intron #1, soybean *FAD3-1A* intron #4 ends, soybean *FATB* intron #2 ends and soybean *FAD3-1A* intron #5).

Step 12 - Soybean *FAD3-1B* intron #4 is PCR amplified using genomic DNA as template and the following primers:

5' Primer = 19516 = CCCAAGCTTGGGGTATCCCATTTAACAC (Adding HindIII site to 5' end)

3' Primer = 19515 = GACCCGGGTCCTGTGAAATTACATATAGAC (Adding XmaCI site to 3' end)

The resulting PCR product is cloned into PCR 2.1 to form KAWHIT03.0090.

Step 13 - To add the soybean *FAD3-1B* intron #4 into KAWHIT03.0077, plasmids KAWHIT03.0090 and KAWHIT03.0077 are digested with HindIII and XmaCI and directionally ligated to make KAWHIT03.0091 (Soybean *FAD2-1A* intron #1, soybean *FAD3-1A* intron #4 ends, soybean *FATB* intron #2 ends, soybean *FAD3-1A* intron #4 and soybean *FAD3-1A* intron #5).

Step 14 - KAWHIT03.0091 is digested with BstXI and SalI and the fragment containing the four introns (Soybean *FAD2-1A* intron #1, soybean *FAD3-1A* intron #4 ends, soybean *FATB* intron #2 ends, soybean *FAD3-1A* intron #4) is gel purified. In a different tube KAWHIT03.0091, is also digested with XhoI and Sse8387I. The four intron fragment is then cloned back into KAWHIT03.0091 in the opposite orientation on the other site of Soy *FAD3-1A* intron #5 to create KAWHIT03.0092 (soybean *FAD2-1A* intron #1 sense, soybean *FAD3-1A* intron #4 ends sense, soybean *FATB* intron #2 ends sense, soybean *FAD3-1A* intron #4 sense, spliceable soybean *FAD3-1A* intron #5, soy *FAD3-1B* intron #4 anti-sense, soybean *FATB*

intron #2 ends anti-sense, soybean *FAD3-1A* intron #4 ends anti-sense, soybean *FAD2-1A* intron #1 anti-sense).

Step 15 - To link the RNAi construct to the 7S alpha' promoter and the TML 3', KAWHIT03.0092 and pMON68527 (7Sa'/TML3' cassette) are digested with SacI and ligated together to make KAWHIT03.0093 0092 (7S alpha' promoter - *FAD2-1A* intron #1 sense, soybean *FAD3-1A* intron #4 ends sense, soybean *FATB* intron #2 ends sense, soybean *FAD3-1A* intron #4 sense, spliceable soybean *FAD3-1A* Intron #5, soy *FAD3-1B* intron #4 anti-sense, soybean *FATB* intron #2 ends anti-sense, soybean *FAD3-1A* intron #4 ends anti-sense, soybean *FAD2-1A* intron #1 anti-sense - TML3').

Step 16 - To introduce the assembled RNAi construct into pMON80612, which contains the selectable maker CP4 fused to the FMV promoter and the RBCS 3', KAWHIT03.0093 and pMON80612 are digested with NotI and ligated together to form pMON68456 (illustrated in Figure 4) comprising a 7S alpha' promoter operably linked to the intron series, double-stranded-RNA-forming construct of *FAD2-1A* intron #1 sense, soybean *FAD3-1A* intron #4 ends sense, soybean *FATB* intron #2 ends sense, soybean *FAD3-1A* intron #4 sense, spliceable soybean *FAD3-1A* intron #5, soy *FAD3-1B* intron #4 anti-sense, soybean *FATB* intron #2 ends anti-sense, soybean *FAD3-1A* intron #4 ends anti-sense, soybean *FAD2-1A* intron #1 anti-sense and TML3' terminator).

Representative sequences for *FAD2-1A*, *FAD2-1B*, *FAD2-2B*, *FAD3-1A*, *FAD3-1B*, and *FAD3-1C* introns include, without limitation, those set forth in U.S. Application Serial Number 10/176,149, filed June 21, 2002, and U.S. Patent Application Serial Number 09/638,508, filed August 11, 2000, and U.S. Provisional Application Serial Number 60/151,224, filed August 26, 1999, and U.S. Provisional Application Serial Number 60/172,128, filed December 17, 1999.

Representative sequences for *FATB* introns include, without limitation, those set forth in U.S. Provisional Application Serial Number 60/390,185, filed June 21, 2002.

**Example 5** – This example illustrates the preparation of a variety of intron dsRNA-forming constructs which can suppress one or a plurality of genes in soybean.

Using the step-wise method illustrated in Example 4, intron dsRNA-forming vectors are constructed to have the following elements:

- 5 (1) 7S promoter – *FAD2-1A* sense intron – *FAD3-1C* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense intron – spliceable *FAD3* intron #5 – *FAD3-1B* anti-sense intron – *FAD3-1A* anti-sense intron – *FAD3-1C* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*;
- (2) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense intron – spliceable *FAD3* intron #5 – *FAD3-1B* anti-sense intron – *FAD3-1A* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*;
- 10 (3) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense intron – spliceable *FAD3* intron #5 – *FAD3-1A* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*;
- (4) 7S promoter – *FAD2-1A* sense intron – spliceable *FAD3* intron #5 – *FAD2-1A* anti-sense intron – pea *rbcS*;
- 15 (5) 7S promoter – *FAD3-1A* sense intron – spliceable *FAD3* intron #5 – *FAD3-1A* anti-sense intron – pea *rbcS*;
- (6) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense 3'UTR – spliceable *FAD3* intron #5 – *FAD3-1A* anti-sense 3'UTR – *FAD2-1A* anti-sense intron – pea *rbcS*; and
- 20 (7) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense 3'UTR – *FAD3-1B* sense 3'UTR – spliceable *FAD3* intron #5 – *FAD3-1B* anti-sense 3'UTR – *FAD3-1A* anti-sense 3'UTR – *FAD2-1A* anti-sense intron – pea *rbcS*;
- (8) 7S promoter – *FATB* sense intron I – *FATB* sense intron II – spliceable *FAD3* intron #5 – *FATB* anti-sense intron II – *FATB* anti-sense intron I – pea *rbcS*;



(9) 7S promoter – *FATB* sense intron II – *FATB* sense intron I – spliceable *FAD3* intron

#5 – *FATB* anti-sense intron I – *FATB* anti-sense intron II – pea *rbcS*;

(10) 7S promoter – *FATB* sense intron – spliceable *FAD3* intron #5 – *FATB* anti-sense intron – pea *rbcS*;

5 (11) 7S promoter – *FAD2-1A* sense intron – *FAD3-1C* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense intron – *FATB* sense intron – spliceable *FAD3* intron #5 – *FATB* anti-sense intron – *FAD3-1B* anti-sense intron – *FAD3-1A* anti-sense intron – *FAD3-1C* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*;

(12) 7S promoter – *FAD2-1A* sense intron – *FAD3-1A* sense intron – *FAD3-1B* sense  
10 intron – *FATB* sense intron – spliceable *FAD3* intron #5 – *FATB* anti-sense intron – *FAD3-1B* anti-sense intron – *FAD3-1A* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*; and

(13) 7S promoter – *FAD2-1A* sense intron sense intron – *FAD3-1A* sense intron – *FATB* sense intron – spliceable *FAD3* intron #5 – *FATB* anti-sense intron – *FAD3-1A* anti-sense intron – *FAD2-1A* anti-sense intron – pea *rbcS*.

15 **Example 6** – This example illustrates plant transformation with the constructs of this invention to produce soybean plants with suppressed genes.

A transformation vector pMON68456 as prepared in Example 4 is used to introduce an intron double-stranded RNA-forming construct into soybean for suppressing the  $\Delta 12$  desaturase,  $\Delta 15$  desaturase, and *FATB* genes. The vector is stably introduced into soybean  
20 (Asgrow variety A4922) via *Agrobacterium tumefaciens* strain ABI (Martinell, U.S. Patent No. 6,384,301). The CP4 selectable marker allows transformed soybean plants to be identified by selection on media containing glyphosate herbicide.

Fatty acid compositions are analyzed from seed of soybean lines transformed with the intron expression constructs using gas chromatography.  $R_1$  pooled seed and  $R_1$  single seed oil  
25 compositions demonstrate that the mono- and polyunsaturated fatty acid compositions were

altered in the oil of seeds from transgenic soybean lines as compared to that of the seed from non-transformed soybean. For instance, *FAD2* suppression provides plants with increased

amount of oleic acid ester compounds; *FAD3* suppression provides plants with decreased

linolenic acid ester compounds; and *FATB* suppression provides plants with reduced saturated

5 fatty ester compounds, e.g. palmitates and stearates. Selections can be made from such lines depending on the desired relative fatty acid composition. Fatty acid compositions are analyzed from seed of soybean lines transformed with constructs using gas chromatography.

**Example 7** – This example illustrates transient expression of constructs for intron double-stranded RNA gene suppression.

10 DNA containing the expression constructs for sense, antisense, and dsRNA expression of the  $\Delta 12$  desaturase,  $\Delta 15$  desaturase, and *FATB* introns is transferred into the nucleus or the cytoplasm of tobacco mesophyll protoplasts. The DNA constructs illustrated in Examples 3, 4, 5 and are introduced by microinjection as described (Crossway et al., (1986) Mol. Gen. Genet. 202: 179-185). Transient gene suppression is observed, e.g., by measuring RNA or fatty acid  
15 compound compositions.

What is claimed is:

1. A nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least one transcribed intron of a gene.
2. The construct of claim 1, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 98% identical to at least one transcribed intron of a gene.
3. The construct of claim 1, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is 100% identical to at least one transcribed intron of a gene.
4. The construct of claim 1, comprising in series one strand of an intron, a spliceable intron, and the complement of said intron, wherein said spliceable intron provides a hairpin structure, and wherein said intron and said complement of said intron can hybridize to each other.
5. The construct of claim 1, wherein said transcribed introns are in *FAD2* genes or *FAD3* genes.
6. The construct of claim 1, comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least two transcribed introns.

7. The construct of claim 6, comprising DNA which is transcribed into RNA that forms two or more double-stranded RNA molecules.

5 8. A transformed cell or organism having in its genome an introduced nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least one transcribed intron of a gene.

10 9. A transformed plant having in its genome an introduced nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least one transcribed intron of a gene.

15 10. The transformed plant of claim 9, having in its genome an introduced nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 98% identical to at least one transcribed intron of a native plant gene.

20 11. The transformed plant of claim 9, wherein said intron is from a *FAD2* gene or a *FAD3* gene.

12. The transformed plant of claim 11, wherein expression of a protein encoded by said

25 *FAD2* gene or said *FAD3* gene is reduced.


13. The transformed plant of claim 11, wherein expression of a protein encoded by said *FAD2* gene or said *FAD3* gene is substantially reduced.

14. The transformed plant of claim 11, wherein expression of the protein encoded by said *FAD2* gene or said *FAD3* gene is effectively eliminated.


15. A method of reducing expression of a protein encoded by a target gene in a mammal comprising introducing into a cell or organism a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least one transcribed intron of a gene.

16. The method of claim 15, wherein the target gene encodes a protein in an insect or nematode which is a pest to a plant, and wherein said method comprises introducing into the genome of said plant a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule which is effective for reducing expression of said target gene when said insect or nematode ingests cells from said plant.


17. A method of reducing expression of a protein encoded by a target gene in a plant comprising introducing into a plant genome a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand of said double-stranded molecule is coded by a portion of said DNA which is at least 90% identical to at least one transcribed intron of a gene.



**Figure 1**



**Figure 2**



**Figure 3**






Figure 4

## SEQUENCE LISTING

&lt;110&gt; Monsanto Technology LLC

&lt;120&gt; Intron Double Stranded RNA Constructs and Uses Thereof

&lt;130&gt; 16517.270

&lt;160&gt; 55

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 420

&lt;212&gt; DNA

&lt;213&gt; Glycine max

```

<400> 1
gtaaattaaa ttgtgcctgc acctcgggat atttcatgtg gggttcatca tatttgttga      60
ggaaaagaaa ctcccgaat tgaattatgc atttatatat cctttttcat ttctagattt      120
cctgaaggct taggtgtagg cacctagcta gtagctacaa tatcagcact tctctctatt      180
gataaacaat tggctgtaat gccgcagtag aggacgatca caacatttcg tgctgggttac      240
tttttgtttt atgggtcatga ttctactctc tctaattctc ccattcattt tgtagttgtc      300
attatcttta gatttttcac tacctggttt aaaattgagg gattgtagtt ctgttggtac      360
atattacaca ttcagcaaaa caactgaaac tcaactgaac ttgtttatac tttgacacag      420

```

&lt;210&gt; 2

&lt;211&gt; 405

&lt;212&gt; DNA

&lt;213&gt; Glycine max

```

<400> 2
gtatgatgct aaattaaatt gtgcctgcac cccaggatat ttcattgtggg attcatcatt      60
tattgaggaa aactctccaa attgaatcgt gcatttatat tttttttcca tttctagatt      120
tcttgaaggc ttatggtata ggcacctaca attatcagca cttctctcta ttgataaaca      180
attggctgta ataccacagt agagaacgat cacaacattt tgtgctgggt accctttggt      240
ttatggtcatt gatcttactc tctctaattc gtcacttccc tccattcatt ttgtacttct      300
catatttttc acttcctggt tgaaaattgt agttctcttg gtacatacta gtattagaca      360
ttcagcaaca acaactgaac tgaacttctt tatactttga cacag                        405

```

&lt;210&gt; 3

&lt;211&gt; 6220

&lt;212&gt; DNA

&lt;213&gt; Glycine max

```

<400> 3
agcttggtac cgagctcgga tccactagta acggccgcca gtgtgctgga attcggcttc      60

```

tctctcacc	tcctcttcac	acattttctg	tgcgctctaa	caaacattct	cgttcacact	120
ttcaggtact	tttctctcct	tatctcttta	tctttattct	ttcctacttt	attgcttaaa	180
ccaatgctat	ctatgcttcg	atctcgctt	cttattttcc	acttcccttt	tctcgcttga	240
tctaaccgtt	ttcgccctcc	gcgcttcgat	tgactgagta	catctacgat	tctctgttct	300
ttcatttcat	agatttcgtc	tgattttggc	taacttgggt	tctgttgccg	ccgattctta	360
catatactga	ttgttttagca	taaatgaact	tgcttgttta	gcactatctg	catattttcg	420
tcacgcatct	ctttcggatc	taaggatgaa	tctcctattt	cctccgtatt	atttctcgta	480
tctcttgttc	tgtgctaata	ctccagaaaa	tggcagcatt	gtcttcttct	ttgctgtata	540
agtgtttgtg	ttgtgaatct	ggaagcgatt	ttgcgtgagg	taacttgcca	cttcaactat	600
tatctttcag	atctcgttta	tttattagct	gctattaatt	tgtgtgtgca	gtgtcaaaact	660
gaagcacacg	actgcttaga	agttagaatt	tgactgactg	ttcctctttg	atttttttct	720
ttcttttctt	tgctwactcg	gcctatttta	tgatctttat	aaatagatta	gtggaccact	780
tggttagttg	gtgagttatg	aatattcgaa	ttttctacca	caagttgggt	taaaaaaatc	840
tctgcaacta	cacgaggatt	ttttatttta	tttagaggaa	actattctgt	catccttttt	900
ccgattacac	ttttctatca	gttgttttga	aatatacacc	ttaggaatat	aatattaccc	960
ctttcgggtc	taatataaat	atattttta	tattttatatt	ttatttaaatg	aaattatttt	1020
taaaataact	tcatttaata	gaatttttaa	taaagttaaa	gacttttatt	gtgtagagtt	1080
taacgaagtt	aattagtttt	cttagtaaat	gtaaaatatg	ccttttttgt	tgtttataat	1140
ggagattgga	aaaaatatac	tttaattttt	ttcaagtgat	gaataattat	ggatgttttg	1200
tcaatatttt	tgtcttgcta	tacaactttc	agtcttgcca	ttaaataatt	ttgaatgtgt	1260
tattgataat	tctgaacaat	atttagagac	gaacataaat	tttatataatt	ttatataatt	1320
tctttttatt	acccttttat	tatcaatttt	gaaatttggt	taatatctgt	gtttcatttt	1380
gaggtctcaa	atttgatata	aggaggttca	aaatgcgttg	ctagccattt	taaagattag	1440
caggagagga	aatgtttctg	gacttaaatt	taaaatatgc	ttatttgttt	ttcaagagag	1500
agagatcaat	atttatataa	tacacttgaa	ttaatataca	ccattgttgc	aaaaaaaaaa	1560
aaatattagt	tgattgtgtg	acaatatttt	atattaaata	taattagtta	atttagttca	1620
agttgagtta	cattttttaca	taccattctt	agccgccact	tttttatatt	tatttgtagg	1680
aataactttt	catctgtatc	aattttcccc	gtctaataaa	aagggtttga	ctttttctta	1740
taatagagtt	tttttttttt	tgctttaagt	tattgtaaaa	taattatttt	attttttttg	1800
cctttgtaaa	ttatgtatat	ttaatgtttt	aataggaaaa	aaatgttatc	aaaagcacta	1860
aaagactaaa	attaaacaac	cataatttgc	aaagatgaaa	ataaaaaaat	aattttgtaa	1920

agataaaaaa tgaaataaaa tagttaaatt ataggaattht aaaagctatt taaatcaaca	1980
aaagttaaag tttctgtaaa aaaagttcaa tttttttttt tattattgaa aaagttaaag	2040
ctaatgagcg ttcgatttgg gttagtatgt agtattttatt attttcaaga ttttggattt	2100
tattgtcgat gtttctgatt tgaatataat ttttttccat tcaacttgtg attttataag	2160
aaaaaaaaag gtacagaaaa aatcaagcgc ttttttttatt tcaattagtg gaggtttcac	2220
tgaaatgggt aaagaatcta ttttgcaatc acaattatta ccggtattca actgcaacaa	2280
ggaacaaaat tcctttcgta aatatacggg gaggaatcta ttttgacttg ttgaatttat	2340
ggtaaagtag aatttagaat ttaattatga gttgaagtaa ttttgaataa tttatatgtt	2400
aaatataaaa ttttgtacta agttttattc ataactttga ttctataata caaacatata	2460
taagttcaaa aataatttta attaaaatta attttatcaa tttttattca aacacgagtc	2520
taatttgctt gatgaattaa gaaaataagg aagaaaatat taaaaactag gagagaagtt	2580
aaagagaatt tcatctttat tattctcagt tgtttcaaaa ataatgaaag gatagctata	2640
taatactgta actgagccaa gaacatattt gccgtccgag taaccttttc ttttcttgtt	2700
ccgttttctc cgccgatgaa gagaggggag ggaatgtatc tttgtattta tgttttoaaa	2760
gagttcgtgc ataaaattgg tttaatcaaa tttttcataa gattattatt ttatgatttt	2820
ttaaaataaa ttagtaacta tattccgtaa gtcgtacaca gttatatgta gtaagtaaat	2880
tatattttaa taattattat cttaaaattt tcttaagaac ttgggttaaaa tatttttgtt	2940
tgaaaaagtt tatgataact tttttttgtt gaaaaaaagt ttacgattat ctaactcgta	3000
cttagattat ttctaattgg gatttattga agggtttttt aagtaaagaa attgtttctt	3060
atggtttctt ttttattgga caaatctacg tagcaaagag tgtttcttaa aaacaagaca	3120
tgtatccttt gaaaaaaaac tatttctttg aaataaaaaa taatatttat ctggcacata	3180
ataatgttaa aattaaatca taattaggta aaaataaaat aaatataaaa gtatgagttt	3240
gttaagtttt ttataatttt ttattattaa agtaaaatta tgtatgattt ttttataatg	3300
atatgatatt ttagggatca caaaaaataa tgtgggtgaat acaaaagtaa ctcaaaaaat	3360
tcatttagta aattttcatt ggagatgcta ttattatgct ttctgattgc tttgtccaaa	3420
aaataaagaa tgttttttta tttgaaaatt gaaaatttct gggtcattgt aagatcttgt	3480
agacggtaac gtcggcctaa agttgtgtga ggggtgttgc atgcaccgat cattaattac	3540
tcgatatgga aaacgactga aataatttaa tttgatgttg ctaatattgg ccatccctct	3600
catcattatt gtttttttat ttgtaacatg acatattctt gtgggtccgc tacggattgg	3660
gtgtttgttg ccaaaaaata caaaatatct gtggaacaag gataaacagt cttgtttgtt	3720
taattgattg attgatgagt ttgcaagcta tatttttaat ttattttaat taaacttttg	3780

tgttttagtt	ctacaatttt	attcatcttg	attttttttt	tacttggcaa	aatcatgatt	3840
ttttaatttt	tacttatgtt	gaaaacaaat	ttattgctaa	aaaaacattt	attctttttt	3900
tagagaaaaa	acaaatttgt	gatatgtagt	gaatcaaagt	aaaattttta	acataatata	3960
gaatactcta	caaatacaatt	ttgagtttct	ttatcatttt	atttatttat	tgacatactt	4020
ctactttctg	caaagaccct	gactcgtgga	agatataggg	aaggttatgg	aagttagtg	4080
attgtcatat	ctagctatct	ttgctaattg	aaaaagcctt	ccctttgttt	acagatctgg	4140
ataaggttgc	atgtttattc	ttttcaactg	tgaatgggtc	tttgcattct	ttttagtata	4200
tgagattaat	gttttaatta	ggaagaagct	tttagaacat	cacccgaatc	caattcgttt	4260
tggtttctgt	gatcttgatg	taaatctata	ctaatttggt	ttgggcagaa	gaaaatgttc	4320
tttgctcaag	tcctctagga	cgaaaatata	aatataacag	ggtatatcag	atctctattc	4380
ttctgtgggt	aatgatagca	tgtttctggt	gttttcttat	tcttcattgg	tcattgataac	4440
ctgctaattc	tatttgccac	gattgagatg	aaaaggtaat	gaactagtaa	acaataatga	4500
gaagaatatg	tcgctactat	tggtgaaacg	gttacgccag	gcacttgagt	atgatgcact	4560
attttaatta	atgcattttt	tttgctttga	tgagaacgca	cattgttcat	tctgattcgg	4620
tgagtttaga	aactattgct	gataatcctt	gatttaagat	tttagtcttg	ttcatgttca	4680
ttaaaagtgt	tgtaaaaaaa	tgactgata	tgtcatgtgc	agattgtgtg	aagatggggg	4740
cgggtggccg	aactgatgtt	cctcctgcca	acaggaagtc	agaggttgac	cctttgaagc	4800
gggtgccatt	tgaaaaacct	ccatttagtc	tcagccaaat	caagaaggtc	attccacctc	4860
actgtttcca	gcgttctgtt	ttccgctcat	tctcctatgt	tgtttacgac	ctcaccatag	4920
ccttctgcct	ctattatgtt	gccacccatt	acttccacct	ccttcccagc	cctctctctt	4980
tcttggcatg	gccaatctac	tgggctgtcc	aagggttgc	ccttactgga	gtttgggtca	5040
ttgcccatga	gtgtggccac	catgcattca	gtgactacca	gttgcttgat	gatattgttg	5100
gccttgctct	ccactccggt	ctcctagtcc	catacttttc	atggaaatac	agccatcgcc	5160
gtcaccactc	caacactggt	tctcttgagc	gggatgaagt	atttgtgcca	aagcagaagt	5220
cctgtatcaa	gtggtactct	aaatacctta	acaatcctcc	aggcagagtc	ctcactcttg	5280
ctgtcaccct	cacacttggt	tggcccttgt	acttggtttt	aatgttttct	ggaaggcctt	5340
atgatagatt	tgcttgccac	tatgacccat	atggtcccat	ttactctgat	cgtgaacgac	5400
ttcaaatata	tatatcagat	gcaggagtac	ttgcagtatg	ctatggcctt	ttccgtcttg	5460
ccatggcaaa	aggacttgcc	tgggtggtgt	gtgtttatgg	agttccattg	ctagtgggtca	5520
atggattttt	ggtgttgatt	acattcttgc	agcatactca	ccctgcattg	ccacattaca	5580
cttcctctga	gtgggactgg	ttgagaggag	ctttagcaac	agtggataga	gattatggaa	5640

tcctgaacaa ggtcttccat aatattacag acactcatgt agcacatcac ttgttctcca 5700  
 caatgccaca ttatcatgca atggaggcta caaaggcaat aaaacccatt ttgggagagt 5760  
 attatcgggtt tgatgagact ccattttgtca aggcaatgtg gagagaggca agagagtgt 5820  
 tttatgtgga gccagatcaa agtaccgaga gcaaagggtg attttggtac aacaataagt 5880  
 tgtgatgatt aatgtagccg aggccttctt gaactttccc ttgtgactgt ttagtatcat 5940  
 ggttgcttat tgggaataat tttgttgaac cctgatgttg gtagtaagta tctagacagt 6000  
 tgcatagcgg ttttgtttac agaataagat atagcctctc tgaacagttt gattattgca 6060  
 ccatggtttg caatcgggtgc atgtcgacca agtttctcaa gactgtggag aagcttattc 6120  
 ttgttccagt tcttgaatcc aagttgttac cgtattctgt aagccgaatt ctgcagatat 6180  
 ccatcacact ggcgccgct cgagcatgca tctagagggc 6220

<210> 4  
 <211> 4597  
 <212> DNA  
 <213> Glycine max

<400> 4  
 gtacttttct ctcccttatct ctttatcttt attctttcct actttattgc ttaaaccaat 60  
 gctatctatg ctccgatctc gccttcttat tttccacttc ccttttctcg cttgatctaa 120  
 ccgttttgcg cctccgcgct tcgattgact gagtacatct acgattctct gttctttcat 180  
 ttcatagatt tcgtctgatt ttggctaact tggtttctgt tgcggcogat tcttacatat 240  
 actgattgtt tagcataaat gaacttgctt gtttagcaact atctgcatat tttcgtcacg 300  
 catctctttc ggatctaagg atgaatctcc tatttccctcc gtattatttc tcgtatctct 360  
 tgttctgtgc taatgctcca gaaaatggca gcattgtctt cttctttgct gtataagtgt 420  
 ttgtgttgtg aatctggaag cgattttgcg tgaggtaact tgcgacttca actattatct 480  
 ttcagatctc gttaatttat tagctgctat taatttgtgt gtgcagtgtc aaactgaagc 540  
 acacgaactgc ttagaagtta gaatttgact gactgttccct ctttgatttt tttctttcct 600  
 ttctttgctw actcggccta tttaatgac tttataaata gattagtgga ccaacttggtt 660  
 agttggtgag ttatgaatat tcgaattttc taccacaagt tgggttaaaa aaatctctgc 720  
 aactacacga ggatttttta ttttatttag aggaaactat tctgtcatcc tttttccgat 780  
 tacacttttc tatcagttgt ttgaaatat acaccttagg aatataatat taccctttc 840  
 ggtcttaata taaatatatt ttaattattt atattttatt taatgaaatt atttttaaaa 900  
 tactttcatt taatagaatt ttaataaag ttaaagactt ttattgtgta gagttaacg 960  
 aagttaatta gttttcttag taaatgtaaa atatgccttt tttgttgttt ataatggaga 1020  
 ttggaaaaaa tatactttaa tttttttcaa gtgatgaata attatggatg ttttgtcaat 1080

atTTTTgtct tgctatacaa ctttcagtct tgccattaaa taattttgaa tgtgttattg	1140
atatctctga acaatatatta gagacgaaca taaattttat atattttata taatttcttt	1200
ttattaccct ttattatca attttgaaat ttggttaata tctgtgtttc attttgaggt	1260
ctcaaatttg atataaggag gttcaaaatg cgttgctagc cattttaaag attagcagga	1320
gaggaaatgt ttctggactt aaatttaaaa tatgcttatt tgtttttcaa gagagagaga	1380
tcaatatatta tataatacac ttgaattaat atacaccatt gttgcaaaaa aaaaaaata	1440
ttagttgatt gtgtgacaat attttatatt aaatataatt agttaattta gttcaagttg	1500
agttacattt ttacatacca ttcttagccg ccactttttt atattttattt gtaggaataa	1560
cttttcatct gtatcaattt tccccgtcta ataaaaaggg ttgactttt tcttataata	1620
gagttttttt ttttttgctt taagttattg taaaataatt attttatttt ttttgccttt	1680
gtaaattatg tatatttaaat gttttaatag gaaaaaatg ttatcaaaag cactaaaaga	1740
ctaaaattaa acaaccataa ttgcaaga tgaaaataaa aaaataattt tgtaaagata	1800
aaaaatgaaa taaaatagtt aaattatagg aatttaaaag ctattttaa atcaaaaagt	1860
taaagtttct gtaaaaaaag ttcaattttt ttttttatta ttgaaaaagt taaagcta at	1920
gagcgttcga ttggggttag tatgtagtat ttattatttt caagattttg gattttattg	1980
tcgatgtttc tgatttgaat ataattattt tccattcaac ttgtgatttt ataagaaaaa	2040
aaaaggtaca gaaaaaatca agcgtttttt ttatttcaat tagtggaggt ttactgaaa	2100
tggttaaaga atctattttg caatcacaat tattaccggt attcaactgc aacaaggaac	2160
aaaattcctt tcgtaaatat acggagagga atctattttg acttggtgaa tttatggtaa	2220
agtagaattt agaattta attgagttga agtaattttg aataatttat atgttaaata	2280
taaaattttg tactaagttt tattcataac ttgatttcta taatacaaac atacataagt	2340
tcaaaaaataa ttttaattaa aattaatttt atcaattttt attcaaacac gagtctaatt	2400
tgcttgatga attaagaaaa taaggaagaa aatatttaaaa actaggagag aagttaaaga	2460
gaatttcac tttattattc tcagttgttt caaaaataat gaaaggatag ctatataata	2520
ctgtaactga gccagaaca ttttgccgt ccgagtaacc ttttcttttc ttgttccgtt	2580
ttctccgccg atgaagagag ggaagggaat gtatctttgt atttatgttt tcaaagagtt	2640
cgtgcataaa attgggtttaa tcaaattttt cataagatta ttattttatg attttttaaa	2700
ataaattagt aactatatcc cgtaagtcgt acacagttat atgtagtaag taaattatat	2760
tttaataatt attatcttaa aattttctta agaacttggt taaaatattt ttgtttgaaa	2820
aagtttatga taactttttt ttgttgaaaa aaagtttacg attatctaac tcgtacttag	2880
attatttcta attgggattt attgaagggt tttttaagta aagaaattgt ttcttatggt	2940

```

ttcttttttta ttggacaaat ttacgtagca aagagtgttt cttaaaaaca agacatgtat 3000
cctttgaaaa aaaactattt ctttgaaata aaaaataata tttatctggc acataataat 3060
gttaaaatta aatcataatt aggtaaaaat aaaataaata taaaagtatg agtttgtaa 3120
gttttttata attttttatt attaaagtaa aattatgtat gattttttta taatgatatg 3180
atattttagg gatcacaaaa aataatgtgg tgaatacaaa agtaactcaa aaaattcatt 3240
tagtaaattt tcattggaga tgctattatt atgctttctg attgctttgt ccaaaaaata 3300
aagaatgttt ttttatttga aaattgaaaa tttctgggtc atgttaagat cttgtagacg 3360
gtaacgtcgg cctaaagttg tgtgaggggt gttgcatgca ccgatcatta attactcgat 3420
atggaaaacg actgaaataa ttaatttga tgttgctaatt attggccatc cctctcatca 3480
ttattgtttt tttatttga acatgacata ttcttgtggg tccgctacgg attgggtgtt 3540
tgttgccaaa aaatacaaaa tatctgtgga acaaggataa acagtcttgt ttgtttaatt 3600
gattgattga tgagtttgca agctatattt ttaatttatt ttaattaaac ttttgtgttt 3660
tagttctaca attttattca tcttgatttt ttttttactt ggcaaaatca tgatttttta 3720
atttttactt atgttgaaaa caaatttatt gctaaaaaaa catttattct ttttttagag 3780
aaaaaacaaa tttgtgatat gtagtgaatc aaatgaaaat tttaaacata atatagaata 3840
ctctacaaat caattttgag tttctttatc attttattta tttattgaca tacttctact 3900
ttctgcaaag accctgactc gtggaagata tagggaaggt tatggaagtt agtgtattgt 3960
catatctagc tatctttgct aattgaaaaa gccttccctt tgtttacaga tctggataag 4020
gttgcatgtt tattcttttc aactgtgaat ggttctttgc atctttttta gtatatgaga 4080
ttaatgtttt aattaggaag aagcttttag aacatcaccc gaatccaatt cgttttggtt 4140
tctgtgatct tgatgtaaat ctataactaat ttggtttggg cagaagaaaa tgttctttgc 4200
tcaagtcctc taggacgaaa atataaatat aacagggtat atcagatctc tattcttctg 4260
tgggtaatga tagcatgttt ctgttgtttt cttattcttc attgggtcatg ataacctgct 4320
aattctattt gccacgattg agatgaaaag gtaatgaact agtaaacaat aatgagaaga 4380
atatgtcgct actattgttg aaacggttac gccaggcact tgagtatgat gcactatttt 4440
aattaatgca ttttttttgc tttgatgaga acgcacattg ttcattctga ttcggtgagt 4500
ttagaaaacta ttgctgataa tccttgattt aagatttttag tcttgttcat gttcattaaa 4560
agtgttgtaa aaaaatgcac tgatatgtca tgtgcag 4597

```

```

<210> 5
<211> 191
<212> DNA
<213> Glycine max

```



<400> 5  
 gtaataatatt ttgtgtttct tactcttttt tttttttttt tgtttatgat atgaatctca 60  
 cacattgttc tgttatgtca tttcttcttc atttggttt agacaactta aatttgagat 120  
 ctttattatg tttttgctta tatggtaaag tgattcttca ttatttcatt cttcattgat 180  
 tgaattgaac a 191

<210> 6  
 <211> 346  
 <212> DNA  
 <213> Glycine max

<400> 6  
 ttagttcata ctggcttttt tgtttgttca tttgtcattg aaaaaaaatc ttttgttgat 60  
 tcaattatatt ttatagtgtg tttggaagcc cgtttgagaa aataagaaat cgcactctgga 120  
 atgtgaaagt tataactatt tagcttcacg tgctgttgca agttctttta ttggttaaatt 180  
 ttttatagcg tgctaggaaa ccatttcgag aaaataagaa atcacatctg gaatgtgaaa 240  
 gttataactg ttagcttctg agtaaactg gaaaaaccac attttggatt tggaacaaaa 300  
 ttttatttga taaatgacaa ccaaattgat ttgatggat ttgca 346

<210> 7  
 <211> 142  
 <212> DNA  
 <213> Glycine max

<400> 7  
 gtatgtgatt aattgcttct cctatagttg ttcttgattc aattacattt tatttatttg 60  
 gtaggtccaa gaaaaaaggg aatctttatg ctctctgagg ctgttcttga acatggctct 120  
 tttttatgtg tcattatctt ag 142

<210> 8  
 <211> 1228  
 <212> DNA  
 <213> Glycine max

<400> 8  
 taacaaaaat aaatagaaaa tagtgggtga acacttaaatt gcgagatagt aatacctaaa 60  
 aaaagaaaaa aatataggta taataaataa tataactttc aaaataaaaa gaaatcatag 120  
 agtctagcgt agtggttgga gtgaaatgat gttcacctac cattactcaa agattttggt 180  
 gtgtccctta gttcattctt attattttac atatcttact tgaaaagact ttttaattat 240  
 tcattgagat cttaaagtga ctgttaaatt aaaataaaaa acaagtttgt taaaacttca 300  
 aataaataag agtgaaggga gtgtcatttg tcttctttct tttattgcgt tattaatcac 360  
 gtttctcttc tctttttttt ttttcttctc tgctttccac ccattatcaa gttcatgtga 420

```

agcagtggcg gatctatgta aatgagtggg gggcaattgc accacaaga ttttattttt 480
tatttgtaca ggaataataa aataaaactt tgccccata aaaaataaat attttttctt 540
aaaataatgc aaaataaata taagaaataa aaagagaata aattattatt aattttatta 600
ttttgtactt tttatttagt ttttttagcg gttagatttt tttttcatga cattatgtaa 660
tcttttaaaa gcatgtaata tttttatttt gtgaaaataa atataaatga tcatattagt 720
ctcagaatgt ataaactaat aataatttta tcactaaaag aaattcta attagtcata 780
aataagtaaa acaagtgaca attatatatt atatttactt aatgtgaaat aatacttgaa 840
cattataata aaacttaatg acaggagata ttacatagtg ccataaagat attttaaaaa 900
ataaaatcat taatacactg tactactata taatattoga tatatatatt taacatgatt 960
ctcaatagaa aaattgtatt gattatatatt tattagacat gaatttaca gccccgtttt 1020
tcatttatag ctcttacctg tgatctattg ttttgcttcg ctgtttttgt tgggtcaagg 1080
acttagatgt cacaatatta atactagaag taaatattta tgaaaacatg taccttacct 1140
caacaaagaa agtgtggtaa gtggcaacac acgtgttgca tttttggccc agcaataaca 1200
cgtgtttttg tgggtgtacta aaatggac 1228

```

<210> 9  
 <211> 625  
 <212> DNA  
 <213> Glycine max

```

<400> 9
gtacatttta ttgcttattc acctaaaaac aatacaatta gtacatttgt tttatctctt 60
ggaagttagt ctttttcagt tgcattgattc taatgctctc tccattctta aatcatgttt 120
tcacaccac ttcatttaaa ataagaacgt ggggtgttatt ttaatttcta ttcactaaca 180
tgagaaatta acttatttca agtaataatt ttaaaatatt tttatgctat tattttatta 240
caaataatta tgtatattaa gtttattgat tttataataa ttatattaaa attatatcga 300
tattaatttt tgattcactg atagtgtttt atattgtag tactgtgcat ttattttaaa 360
attggcataa ataatatatg taaccagctc actatactat actgggagct tgggtggtgaa 420
aggggttccc aaccctcctt tctaggtgta catgctttga tacttctggt accttcttat 480
atcaatataa attatatatt gctgataaaa aaacatggtt aaccattaaa ttcttttttt 540
aaaaaaaaa ctgtatctaa actttgtatt attaaaaaga agtctgagat taacaataaa 600
ctaacactca tttgattca ctgca 625

```

<210> 10  
 <211> 98  
 <212> DNA

&lt;213&gt; Glycine max

&lt;400&gt; 10

ggtagtgat tttttgactt ggaagacaac aacacattat tattataata tgggtcaaaa 60

caatgacttt ttctttatga tgtgaactcc atttttta 98

&lt;210&gt; 11

&lt;211&gt; 115

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;400&gt; 11

ggtaactaaa ttactcctac attgttactt tttcctcctt ttttttatta tttcaattct 60

ccaattggaa atttgaaata gttaccataa ttatgtaatt gtttgatcat gtgca 115

&lt;210&gt; 12

&lt;211&gt; 148

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;223&gt; FAD3-1B intron 3c

&lt;400&gt; 12

gtaatctcac tctcacactt tctttataca tcgcacgcca gtgtgggtta tttgcaacct 60

acaccgaagt aatgccctat aattaatgag gttaacacat gtccaagtcc aatattttgt 120

tcacttattt gaacttgaac atgtgtag 148

&lt;210&gt; 13

&lt;211&gt; 361

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;223&gt; FAD3-1B intron 4

&lt;400&gt; 13

gtatcccatt taacacaatt tgtttcatta acattttaag agaatttttt tttcaaaaata 60

gttttcgaaa ttaagcaaatt accaagcaaa ttgtagatc tacgcttgta cttgttttaa 120

agtcaaattc atgaccaaatt tgcctcaca agtccaaacc gtccactatt ttattttcac 180

ctactttata gcccaatttg ccatttggtt acttcagaaa agagaacccc atttgtagta 240

aatatattat ttatgaatta tggtagtttc aacataaaac atacttatgt gcagttttgc 300

catccttcaa aagaaggtag aaacttactc catgttactc tgtctatatg taatttcaca 360

g 361

&lt;210&gt; 14

&lt;211&gt; 1037

&lt;212&gt; DNA

&lt;213&gt; Glycine max

<400> 14  
 gtaacaaaaa taaatagaaa atagtgagtg aacacttaaa tgtagatac taccttcttc 60  
 ttcttttttt tttttttttt gaggttaatg ctagataata gctagaaaga gaaagaaaga 120  
 caaatatagg taaaaataaa taatataacc tgggaagaag aaaacataaa aaaagaaata 180  
 atagagtcta cgtaatgttt ggatttttga gtgaaatggg gttcacctac cattactcaa 240  
 agattctggt gtctacgtag tgtttgact ttggagtga atgggtgttca cctaccatta 300  
 ctcagattct gttgtgtccc ttagttactg tcttatattc ttaggtata ttctttattt 360  
 tacatccttt tcacatctta cttgaaaaga ttttaattat tcattgaaat attaacgtga 420  
 cagttaaatt aaaataataa aaaattcggt aaaacttcaa ataaataaga gtgaaaggat 480  
 catcattttt cttctttctt ttattgcgtt attaatcatg cttctcttct ttttttctt 540  
 cgctttccac ccatatcaaa ttcattgtga gtatgagaaa atcacgattc aatggaaagc 600  
 tacaggaacy ttttttggtt tgtttttata atcggaatta atttatactc cattttttca 660  
 caataaatgt tacttagtgc cttaaagata atatttgaaa aattaaaaaa attattaata 720  
 cactgtacta ctatataata ttgacatat atttaacatg attttctatt gaaaatttgt 780  
 atttattatt ttttaatcaa aacccataag gcattaattt acaagacca ttttccattt 840  
 atagctttac ctgtgatcat ttatagcttt aagggactta gatgttaca tcttaattac 900  
 aagtaaatat ttatgaaaaa catgtgtctt accccttaac cttacctcaa caaagaaagt 960  
 gtgataagtg gcaacacacg tggtgctttt ttggcccagc aataacacgt gtttttggtg 1020  
 tgtacaaaaa tggacag 1037

<210> 15  
 <211> 4497  
 <212> DNA  
 <213> Glycine max

<400> 15  
 cttgcttggt aacaacgtcg tcaagttatt atttgttct tttttttttt atcatatttc 60  
 ttattttggt ccaagtatgt catattttga tccatcttga caagtagatt gtcattgagg 120  
 aataggaata tcaactttaa ttttaaagca ttgattagtc tgtaggcaat attgtcttct 180  
 tcttcctcct tattaatatt ttttattctg ccttcaatca ccagttatgg gagatggatg 240  
 taatactaaa taccatagtt gttctgcttg aagtttagtt gtatagttgt tctgcttgaa 300  
 gtttagttgt gtgtaatgtt tcagcgttgg cttccctgt aactgctaca atggactga 360  
 atatataatt tttgcattgt tcattttttt cttttactta atcttcattg ctttgaaatt 420  
 aataaaacaa aaagaaggac cgaatagttt gaagtttgaa ctattgccta ttcattgtaac 480

ttattcaccc aatcttatat agtttttctg gtagagatca ttttaaattg aaggatataa	540
attaagagga aatacttgta tgtgatgtgt ggcaatttgg aagatcatgc gtagagagtt	600
taatggcagg ttttgcaaat tgacctgtag tcataattac actgggacct ctcgagagttt	660
tgtgcctttt tgttgtcgct gtgtttgggt ctgcatgtta gcctcacaca gatatttagt	720
agttgttggt ctgcatataa gcctcacacg tataactaac gagtgaacct caaaatcatg	780
gccttacacc tattgagtga aattaatgaa cagtgcattg gagtatgtga ctgtgacaca	840
acccccggtt ttcataattgc aatgtgctac tgtggtgatt aaccttgcta cactgtcgtc	900
cttgtttggt tccttatgta tattgatacc ataaattatt actagtatat ctttttatat	960
tgtccatacc attacgtgtt tatagtctct ttatgacatg taattgaatt ttttaattat	1020
aaaaaataat aaaacttaat tacgtactat aaagagatgc tcttgactag aattgtgatc	1080
tcctagtttc ctaaccatat actaatattt gcttgtattg atagccctc cgttcccaag	1140
agtataaac tgcacgaat aatacaagcc actaggcatg gttaaattaaa ttgtgcctgc	1200
acctcgggat atttcatgtg gggttcatca ttttgttga ggaaaagaaa ctcccgaat	1260
tgaattatgc atttatatat ctttttcat ttctagattt cctgaaggct taggtgtagg	1320
cacctagcta gtagctacaa tatcagcact tctctctatt gataaacaat tggctgtaat	1380
gccgcagtag aggacgatca caacatttcg tgotggttac ttttgtttt atggcatga	1440
tttcaactctc tctaactctc ccattcattt tgtagttgtc attatcttta gatttttcac	1500
tacctgggtt aaaattgagg gattgtagtt ctgttggtac atattacaca ttcagcaaaa	1560
caactgaaac tcaactgaac ttgtttatac tttagacacag ggtctagcaa aggaaacaac	1620
aatgggaggt agaggtcgtg tggcaaagtg gaagttcaag ggaagaagcc tctctcaagg	1680
gttccaaaca caaagccacc attcactgtt ggccaactca agaaagcaat tccaccacac	1740
tgctttcagc gctccctcct cacttcattc tcctatgttg tttatgacct ttcatttgcc	1800
ttcattttct acattgccac cacctacttc cacctccttc ctcaaccctt ttccctcatt	1860
gcatggccaa tctattgggt tctccaaggt tgccttctca ctggtgtgtg ggtgattgct	1920
cacgagtgtg gtcaccatgc cttcagcaag taccaatggg ttgatgatgt tgtgggtttg	1980
acctttcact caacactttt agtcccttat ttctcatgga aaataagcca tcgccgccat	2040
cactccaaca caggttcctt tgacctgat gaagtgtttg tcccaaaacc aaaatccaaa	2100
gttgcatggt tttccaagta cttaacaac cctctaggaa gggctgtttc tcttctcgtc	2160
acactcacia taggggtggcc tatgtattta gccttcaatg tctctggtag acctatgat	2220
agttttgcaa gccactacca cccttatgct cccatatatt ctaaccgtga gaggcttctg	2280
atctatgtct ctgatgttgc tttgttttct gtgacttact ctctctaccg tgttgcaacc	2340

ctgaaagggg	tgggttggct	gctatgtgtt	tatgggggtgc	ctttgctcat	tgtgaacggt	2400
ttttcttgta	ctatcacata	tttgcagcac	acacactttg	ccttgccctca	ttacgattca	2460
tcagaatggg	actggctgaa	gggagctttg	gcaactatgg	acagagatta	tgggattctg	2520
aacaaggtgt	ttcatcacat	aactgatact	catgtggctc	accatctctt	ctctacaatg	2580
ccacattacc	atgcaatgga	ggcaaccaat	gcaatcaagc	caatattggg	tgagtactac	2640
caatttgatg	acacaccatt	ttacaaggca	ctgtggagag	aagcgagaga	gtgcctctat	2700
gtggagccag	atgaaggaac	atccgagaag	ggcgtgtatt	ggtacaggaa	caagtattga	2760
tggagcaacc	aatgggccat	agtgggagtt	atggaagttt	tgtcatgtat	tagtacataa	2820
ttagtagaat	gttataaata	agtggatttg	ccgcgtaatg	actttgtgtg	tattgtgaaa	2880
cagcttggtg	cgatcatggt	tataatgtaa	aaataattct	ggtattaatt	acatgtggaa	2940
agtgttctgc	ttatagcttt	ctgcctaaaa	tgcacgctgc	acgggacaat	atcattggta	3000
atTTTTTTaa	aatctgaatt	gaggctactc	ataatactat	ccataggaca	tcaaagacat	3060
gttgcaattga	ctttaagcag	aggttcatct	agaggattac	tgcataaggct	tgaactacaa	3120
gtaattttaag	ggacgagagc	aactttagct	ctaccacgct	gttttacaag	gttattaaaa	3180
tcaaattgat	cttattaaaa	ctgaaaattt	gtaataaaat	gctattgaaa	aattaaaata	3240
tagcaaacac	ctaaattgga	ctgattttta	gattcaaatt	taataattaa	tctaaattaa	3300
acttaaattt	tataatatat	gtcttgtaat	atatcaagtt	ttttttttta	ttattgagtt	3360
tggaaacata	taataaggaa	cattagttaa	tattgataat	ccactaagat	cgacttagta	3420
ttacagtatt	tggatgattt	gtatgagata	ttcaaacttc	actcttatca	taatagagac	3480
aaaagttaat	actgatgggtg	gagaaaaaaa	aatggtattg	ggagcatatg	gtaagataag	3540
acggataaaa	atatgctgca	gcctggagag	ctaattgtatt	ttttggtgaa	gttttcaagt	3600
gacaactatt	catgatgaga	acacaataat	atTTTctact	tacctatccc	acataaaaata	3660
ctgattttta	taatgatgat	aaataatgat	taaaatatTT	gattctttgt	taagagaaat	3720
aaggaaaaaca	taaatattct	catggaaaaa	tcagcttgta	ggagtagaaa	ctttctgatt	3780
ataattttta	tcaagtttaa	ttcattcttt	taattttatt	attagtacaa	aatcattctc	3840
ttgaatttag	agatgtatgt	tgtagcttaa	tagtaatttt	ttatttttat	aataaaaattc	3900
aagcagtcaa	atttcatcca	aataatcgtg	ttcgtgggtg	taagtcagtt	attccttctt	3960
atcttaatat	acacgcaaag	gaaaaaataa	aaataaaatt	cgaggaagcg	cagcagcagc	4020
tgataccacg	ttggttgacg	aaactgataa	aaagcgtgtg	cattgtgtct	ttgtttgatc	4080
atcttcacaa	tcacatctcc	agaacacaaa	gaagagtgac	ccttcttctt	gttattccac	4140
ttgcgttagg	tttctacttt	cttctctctc	tctctctctc	tcttcattcc	tcatttttcc	4200

ctcaaacaat caatcaattt tcattcagat tcgtaaattt ctcgattaga tcacgggggt 4260  
 aggtctccca ctttatcttt tccaagcct ttctctttcc ccctttccct gtctgcccc 4320  
 taaaattcag gatcggaac gaactgggtt cttgaatttc actctagatt ttgacaaatt 4380  
 cgaagtgtgc atgcactgat gcgacccact cccctttttt tgcattaaac aattatgaat 4440  
 tgagggtttt cttgcgatca tcattgcttg aattgaatca tattagggtt agattct 4497

<210> 16  
 <211> 18  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer

<400> 16  
 atacaagcca ctaggcat 18

<210> 17  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer

<400> 17  
 gattggccat gcaatgaggg aaaagg 26

<210> 18  
 <211> 778  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <221> misc\_feature  
 <222> (1)..(778)  
 <223> unsure at all n locations

<220>  
 <223> PCR primer

<400> 18  
 atacaagcca ctaggcatgg taaattaaat tgtgcctgca cctcgggata tttcatgtgg 60  
 ggttcatcat atttgttgag gaaaagaaac tcccgaaatt gaattatgca tttatatatc 120  
 ctttttcatt tctagatttc ctgaaggcct aggtgtaggc acctagctag tagctacaat 180  
 atcagcactt ctctctattg ataaacaatt ggctgtaatg ccgcagtaga ggacgatcac 240  
 aacatttcgt gctgggttact ttttgtttta tggatcatgat ttcactctct ctaatctctc 300  
 cattcatttt gtagttgtca ttatcttttag atttttcact acctgggttta aaattgaggg 360  
 attgtagttc tgttggtaca tattacacat tcagcaaaac aactgaaact caactgaact 420

tgtttataact ttgacacagg gtctagcaaa ggaacaaca atgggaggta gaggtcgtgt 480  
 ggccaaagtg gaagttcaag ggaagaagcc tctctcaagg gttccaaaca caaagccacc 540  
 attcactggt ggccaactca agaaagcaat tccaccacac tgctttcagc gctccctcct 600  
 cacttcattc tctatgttg tttatgacct ttcatTTGCC ttcatTTTct acattgccac 660  
 cacctacttc cacctccttc ctcaaccctt ttcctcatt gcatggccaa tcaagccgaa 720  
 ttctgcagat atccatcaca tggcggcggn tggngnaggn ntntanaggg cccaattc 778

<210> 19  
 <211> 2463  
 <212> DNA  
 <213> Glycine max

<400> 19  
 actatagggc acgctggtc gacggcccgg gctggtcctc ggtgtgactc agccccaagt 60  
 gacgccaacc aaacgcgtcc taactaaggt gtagaagaaa cagatagtat ataagtatac 120  
 catataagag gagagtgagt ggagaagcac ttctcctttt tttttctctg ttgaaattga 180  
 aagtgttttc cgggaaataa ataaaataaa ttaaaatcct acacactcta ggtaggtact 240  
 tctaatttaa tccacacttt gactctatat atgttttaaa aataattata atgcgtactt 300  
 acttctcat tatactaaat ttaacatcga tgattttatt ttctgtttct cttctttcca 360  
 cctacatata tcccaaaatt tagggtgcaa ttttaagttt attaacacat gtttttagct 420  
 gcatgctgcc tttgtgtgtg ctcaccaa at tgcattcttc tctttatatg ttgtatttga 480  
 attttcacac catatgtaaa caagattacg tacgtgtcca tgatcaaata caaatgctgt 540  
 cttatactgg caatttgata aacagccgtc cttttttct ttttctctt aactatatat 600  
 gctctagaat ctctgaagat tcctctgcca tcgaatttct ttcttggtaa caacgtcgtc 660  
 gttatgttat tattttattc tatttttatt ttatcatata tatttcttat tttgttcgaa 720  
 gtatgtcata ttttgatcgt gacaattaga ttgtcatgta ggagtaggaa tatcacttta 780  
 aaacattgat tagtctgtag gcaatattgt cttcttttct ctcctttatt aatataattt 840  
 gtogaagttt taccacaagg ttgattcgt tttttgtcc ctttctcttg ttctttttac 900  
 ctcaggattt ttagtctttc atggattata agatcactga gaagtgtatg catgtaatac 960  
 taagcaccat agctgttctg cttgaattta tttgtgtgta aattgtaatg tttcagcgtt 1020  
 ggctttccct gtagctgcta caatggfact gtatatctat tttttgcatt gttttcattt 1080  
 tttcttttac ttaatcttca ttgctttgaa attaataaaa caatataata tagtttgaac 1140  
 tttgaactat tgcctattca tgtaattaac ttattcactg actcttattg tttttctggt 1200  
 agaattcatt ttaaattgaa ggataaatta agaggcaata cttgtaaatt gacctgtcat 1260



aattacacag gaccctgttt tgtgcctttt tgtctctgtc tttgggttttg catggttagcc 1320  
tcacacagat atttagtagt tgttctgcat acaagcctca cacgtataact aaaccagtgg 1380  
acctcaaagt catggcctta cacctattgc atgcgagtct gtgacacaac ccctgggttc 1440  
catattgcaa tgtgctacgc cgtcgtcctt gtttgtttcc atatgtatat tgataccatc 1500  
aaattattat atcattttata tggctctggac cattacgtgt actctttatg acatgtaatt 1560  
gagtttttta attaaaaaaa tcaatgaaat ttaactacgt agcatcatat agagataatt 1620  
gactagaaat ttgatgactt attctttcct aatcatatct tcttgtattg atagccccgc 1680  
tgtccctttt aaactcccga gagagtataa aactgcatcg aatattacaa gatgcactct 1740  
tgtcaaatga agggggggaa atgatactac aagccactag gcatgggatg atgctaaatt 1800  
aaattgtgcc tgcaccccag gatatttcat gtgggattca tcattttattg aggaaaactc 1860  
tccaaattga atcgtgcatt tatatttttt ttccatttct agatttcttg aaggcttatg 1920  
gtataggcac ctacaattat cagcacttct ctctattgat aaacaattgg ctgtaatacc 1980  
acagtagaga acgatcaca ctttttgtgc tggttacctt ttgttttatg gtcattgattt 2040  
cactctctct aatctgtcac ttccctccat tcattttgta cttctcatat ttttcacttc 2100  
ctggttgaaa attgtagttc tcttgggtaca tactagtatt agacattcag caacaacaac 2160  
tgaactgaac ttcttttatac ttgacacag ggtctagcaa aggaaacaat aatgggaggt 2220  
ggaggccgtg tggccaaagt tgaaattcag cagaagaagc ctctctcaag ggttccaaac 2280  
acaaagccac cattcactgt tggccaactc aagaaagcca ttccaccgca ctgctttcag 2340  
cgttccctcc tcacttcatt gtcctatggt gtttatgacc tttcattggc tttcattttc 2400  
tacattgcca ccacctactt ccacctcctc cctcaccctt tttccctcat tgcattggcca 2460  
atc 2463

<210> 20  
<211> 44  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 20  
cuacuacuac uactcgagac aaagccttta gccttttagcc tatg 44

<210> 21  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 21  
caucaucauc auggatccca tgtctctcta tgcaag 36

<210> 22  
<211> 1704  
<212> DNA  
<213> Glycine max

<400> 22  
actatagggc acgcgtgggc gacggcccg gctggctctc ggtgtgactc agccccaagt 60  
gacgcccaacc aaacgcgtcc taactaaggt gtagaagaaa cagatagtat ataagtatac 120  
catataagag gagagtgagt ggagaagcac ttctcctttt tttttctctg ttgaaattga 180  
aagtgttttc cgggaaataa ataaaataaa ttaaaatctt acacactcta ggtaggtact 240  
tctaatttaa tccacacttt gactctatat atgttttaaa aataattata atgcgtactt 300  
acttctcat tataactaaat ttaacatcga tgattttatt ttctgtttct cttctttcca 360  
cctacatata tcccaaaatt tagggtgcaa ttttaagttt attaacacat gtttttagct 420  
gcatgctgcc ttgtgtgtg ctcaccaaatt tgcattcttc tctttatatg ttgtatttga 480  
attttcacac catatgtaaa caagattacg tacgtgtcca tgatcaaata caaatgctgt 540  
cttatactgg caatttgata aacagccgtc cttttttct tttctctttt aactatatat 600  
gctctagaat ctctgaagat tcctctgcc tgaatttct ttcttggtta caacgtcgtc 660  
gttatgttat tattttattc tatttttatt ttatcatata tatttcttat ttgtttcgaa 720  
gtatgtcata ttttgatcgt gacaattaga ttgtcatgta ggagtaggaa tatcacttta 780  
aaacattgat tagtctgtag gcaatattgt cttcttttct ctcctttatt aatatatttt 840  
gtcgaagttt taccacaagg ttgattcgtc tttttgtcc cttctctctg ttctttttac 900  
ctcaggtatt ttagtctttc atggattata agatcactga gaagtgtatg catgtaatac 960  
taagcaccat agctgttctg cttgaattta ttgtgtgta aattgtaatg tttcagcgtt 1020  
ggctttccct gtagctgcta caatggtagt gtatatctat tttttgcatt gttttcattt 1080  
tttcttttac ttaatcttca ttgctttgaa attaataaaa caatataata tagtttgaac 1140  
tttgaactat tgcctattca tgtaattaac ttattcactg actcttattg tttttctggc 1200  
agaattcatt ttaaattgaa ggataaatta agaggcaata cttgtaaatt gacctgtcat 1260  
aattacacag gaccctgttt tgtgcctttt tgtctctgtc tttggttttg catgttagcc 1320  
tcacacagat atttagtagt tgttctgcat acaagcctca cacgtatact aaaccagtgg 1380  
acctcaaagt catggcctta cacctattgc atgcgagtct gtgacacaac ccctggtttc 1440  
catattgcaa tgtgctacgc cgtcgtcctt gtttgtttcc atatgtatat tgataccatc 1500  
aaattattat atcatattata tggctctggac cattacgtgt actctttatg acatgtaatt 1560

gagtttttta attaaaaaaa tcaatgaaat ttaactacgt agcatcatat agagataatt 1620  
 gactagaaat ttgatgactt attctttcct aatcatatatt tcttgatttg atagccccgc 1680  
 tgtccctttt aaactcccgga gaga 1704

<210> 23  
 <211> 4010  
 <212> DNA  
 <213> Glycine max

<400> 23  
 acaaagcctt tagcctatgc tgccaataat ggataccaac aaaagggttc ttcttttgat 60  
 ttgataccta gcgctcctcc accgtttaag attgcagaaa tcagagcttc aataccaaaa 120  
 cattgctggg tcaagaatcc atggagatcc ctacagttatg ttctcaggga tgtgcttgta 180  
 attgctgcat tgggtgctgc agcaattcac ttcgacaact ggcttctctg gctaattctat 240  
 tgccccattc aaggcacaat gttctgggct ctctttgttc ttggacatga ttggaataa 300  
 tttttgtgtt tcttactctt tttttttttt ttttgtttat gatatgaatc tcacacattg 360  
 ttctgttatg tcatttcttc ttcatattgc tttagacaac ttaaatttga gatctttatt 420  
 atgtttttgc ttatatggtg aagtgattct tcattatttc attcttcatt gattgaattg 480  
 aacagtggcc atggaagctt ttcagatagc cctttgctga atagcctggt gggacacatc 540  
 ttgcattcct caattcttgt gccataccat ggatggtagg ttcatactgg cttttttgtt 600  
 tgttcatttg tcattgaaaa aaaatctttt gttgattcaa ttatttttat agtgtgtttg 660  
 gaagcccgtt tgagaaaaata agaaatcgca tctggaatgt gaaagttata actatttagc 720  
 ttcatctgtc gttgcaagtt cttttattgg ttaaattttt atagcgtgct aggaaaccca 780  
 ttcgagaaaa taagaaatca catctggaat gtgaaagtta taactgttag cttctgagta 840  
 aacgtggaaa aaccacattt tggatttggg accaaatttt atttgataaa tgacaaccaa 900  
 attgattttg atggattttg caggagaatt agccacagaa ctaccatga aaaccatgga 960  
 cacattgaga aggatgagtc atgggttcca gtatgtgatt aattgcttct cctatagttg 1020  
 ttcttgattc aattacattt tatttatttg gtaggtccaa gaaaaaaggg aatctttatg 1080  
 cttctgagg ctgttcttga acatggctct tttttatgtg tcattatctt agttaacaga 1140  
 gaagatttac aagaatctag acagcatgac aagactcatt agattcactg tgccatttcc 1200  
 atgtttgtgt atccaattta tttggtgagt gattttttga cttggaagac aacaacacat 1260  
 tattattata atatggttca aaacaatgac tttttcttta tgatgtgaac tccatttttt 1320  
 agttttcaag aagccccgga aaggaaggct ctacttcaa tccctacagc aatctgtttc 1380  
 caccagtgga gagaaaagga atagcaatat caacactgtg ttgggctacc atgttttctc 1440

tgcttatcta tctctcattc attaactagt ccacttctag tgctcaagct ctatggaatt	1500
ccatattggg taactaaatt actcctacat tgttactttt tcctcctttt ttttattatt	1560
tcaattctcc aattggaaat ttgaaatagt taccataatt atgtaattgt ttgatcatgt	1620
gcagatgttt gttatgtggc tggactttgt cacatacttg catcaccatg gtcaccacca	1680
gaaactgcct tggtagcgcg gcaaggtaac aaaaataaat agaaaatagt ggggtgaacac	1740
ttaaatgcga gatagtaata cctaaaaaaaa gaaaaaata taggtataat aaataatata	1800
actttcaaaa taaaaagaaa tcatagagtc tagcgtagtg tttggagtga aatgatgttc	1860
acctaccatt actcaaagat tttgttgtgt cccttagttc attcttatta ttttacatat	1920
cttacttgaa aagacttttt aattattcat tgagatctta aagtgactgt taaattaaaa	1980
taaaaaacia gtttggttaa acttcaaata aataagagtg aaggagtggt catttgtctt	2040
ctttctttta ttgcgttatt aatcacgttt ctcttctctt tttttttttt cttctctgct	2100
ttccacccat tatcaagttc atgtgaagca gtggcggatc tatgtaaagtg agtggggggc	2160
aattgcaccc acaagatttt attttttatt tgtacaggaa taataaaata aaactttgccc	2220
cccataaaaa ataaatatatt tttcttaaaa taatgcaaaa taaatataag aaataaaaag	2280
agaataaatt attattaatt ttattatttt gtacttttta tttagttttt ttagcggtta	2340
gatttttttt tcatgacatt atgtaatctt ttaaaagcat gtaatatattt tatttttgtga	2400
aaataaatat aatgatcat attagtctca gaatgtataa actaataata attttatcac	2460
taaaagaaat tctaatttag tccataaata agtaaaacia gtgacaatta tattttatat	2520
ttacttaatg tgaaataata cttgaacatt ataataaac ttaatgacag gagatattac	2580
atagtgccat aaagatatatt taaaaataa aatcattaat acactgtact actatataat	2640
attcgatata tatttttaac atgattctca atagaaaaat tgtattgatt atattttatt	2700
agacatgaat ttacaagccc cgtttttcat ttatagctct tacctgtgat ctattgtttt	2760
gcttcgctgt ttttggttgt caagggactt agatgtcaca atattaatac tagaagtaaa	2820
tatttatgaa aacatgtacc ttacctcaac aaagaaagtg tggttaagtgg caacacacgt	2880
gttgcatttt tggcccagca ataacacgtg tttttgttgt gtactaaaat ggacaggaat	2940
ggagtatttt aagaggtggc ctcaccactg tggatcgtga ctatggttgg atcaataaca	3000
ttcaccatga cattggcacc catgttatcc accatctttt ccccaaat cctcattatc	3060
acctcgttga agcggtagat tttattgctt attcacctaa aaacaataca attagtacat	3120
ttgttttatc tcttggaagt tagtcatttt cagttgcatg attctaatagc tctctccatt	3180
cttaaatcat gttttcacac ccacttcatt taaaataaga acgtgggtgt tatttttaatt	3240
tctattcact aacatgagaa attaacttat ttcaagtaat aattttaaaa tatttttatg	3300

ctattatattt attacaaata attatgtata ttaagtttat tgattttata ataattatat 3360  
 taaaattata tcgatattaa tttttgattc actgatagtg ttttatattg ttagtactgt 3420  
 gcatttatatt taaaattggc ataaataata tatgtaacca gctcactata ctatactggg 3480  
 agcttggttg tgaaaggggt tcccaaccct cctttctagg tgtacatgct ttgatacttc 3540  
 tgggtaccttc ttatatcaat ataaattata ttttgctgat aaaaaaacat ggtaaacat 3600  
 taaattcttt ttttaaaaaa aaaactgtat ctaaaactttg tattattaaa aagaagtctg 3660  
 agattaacaa taaactaaca ctcatattga ttcactgcag acacaagcag caaaaccagt 3720  
 tcttgagat tactaccgtg agccagaaag atctgcgcca ttaccatttc atctaataaa 3780  
 gtatttaatt cagagtatga gacaagacca cttcgtaagt gacactggag atgttggtta 3840  
 ttatcagact gattctctgc tctccactc gcaacgagac tgagtttcaa actttttggg 3900  
 ttattattta ttgattctag ctactcaaat tacttttttt ttaatgttat gttttttgga 3960  
 gttaacggtt ttctgaacaa cttgcaaatt acttgcatag agagacatgg 4010

<210> 24  
 <211> 34  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer

<400> 24  
 acgaattcct cgaggtaaatt taaattgtgc ctgc 34

<210> 25  
 <211> 33  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer

<400> 25  
 gcgagatcta tcgatctgtg tcaaagtata aac 33

<210> 26  
 <211> 19  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> PCR primer

<400> 26  
 catgctttct gtgcttctc 19

<210> 27

<211> 19  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 27  
gttgatccaa ccatagtcg

19

<210> 28  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 28  
gcgatcgatg tatgatgcta aattaaattg tgcctg

36

<210> 29  
<211> 30  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 29  
gcggaattcc tgtgtcaaag tataaagaag

30

<210> 30  
<211> 30  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 30  
gatcgatgcc cggggtaata atttttgtgt

30

<210> 31  
<211> 29  
<212> DNA  
<213> Artificial sequence

<220>  
<223> PCR primer

<400> 31  
cacgcctcga gtgttcaatt caatcaatg

29

<210> 32  
<211> 24  
<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 32

cactcgagtt agttcatact ggct

24

<210> 33

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 33

cgcatcgatt gcaaaatcca tcaaa

25

<210> 34

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 34

cuacuacuac uactcgagcg taaatagtgg gtgaacac

38

<210> 35

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 35

caucaucauc auctcgagga attcgtccat tttagtacac c

41

<210> 36

<211> 39

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 36

cuacuacuac uactcgaggc gcgtacattt tattgctta

39

<210> 37

<211> 41

<212> DNA

<213> Artificial sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 37

caucaucauc auctcgagga attctgcagt gaatccaaat g

41

&lt;210&gt; 38

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 38

caccatggtc atcatcagaa ac

22

&lt;210&gt; 39

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; PCR primer

&lt;400&gt; 39

tcacgatcca cagttgtgag ac

22

&lt;210&gt; 40

&lt;211&gt; 4086

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;223&gt; soybean FATB genomic clone

&lt;400&gt; 40

ttagggaaac aacaaggacg caaaatgaca caatagccct tcttccctgt ttccagcttt	60
tctccttctc tctctccatc ttcttcttct tcttcaotca gtcaggtagc caaacaatc	120
tgctattcat tcattcatte ctctttctct ctgatcgcaa actgcacctc tacgctccac	180
tcttctcatt ttctcttcct ttctcgcttc tcagatccaa ctcttcagat aacacaagac	240
caaaccgct ttttctgcat ttctagacta gacgttctac cggagaaggt tctcgattct	300
tttctctttt aactttatth ttaaaataat aataatgaga gctggatgag tctgttcggt	360
gtgaatttcg aggcaatggg gttctcattt tcgttacagt tacagattgc attgtctgct	420
ttcctcttct ccttggttct tttgccttgt ctgatttttc gtttttattt cttactttta	480
atthttgggg atggatattt tttctgcatt ttttcggttt gcgatgtttt caggattccg	540
attccgagtc agatctgcgc cggcttatac gacgaatttg ttcttattcg caacttttcg	600
cttgattggc ttgttttacc tctggaatct cacacgtgat caaataagcc tgctatttta	660



gttgaagtag aatttgttct ttatcggaag gaattctatg gatctgttct gaaattggag	720
ctactgtttc gagttgctat tttttttagt agtattaaga acaagtttgc cttttatatt	780
acattttttt cctttgcttt tgccaaaagt ttttatgac actctcttct gtttgtgata	840
taactgatgt gctgtgctgt tattatttgt tatttggggg gaagtataat tttttgggtg	900
aacttggagc attttttagtc cgattgattt ctcgatatca ttttaaggcta aggttgacct	960
ctaccacgcg tttgcgtttg atgttttttc cttttttttt ttatctcata tcttttacag	1020
tgtttgccta tttgcatttc tcttctttat cccctttctg tggaaagggtg ggagggaaaa	1080
tgtatttttt ttttctcttc taacttgcgt atattttgca tgcagcgacc ttagaaattc	1140
attatgggtg caacagctgc tacttcatca tttttccctg ttacttcacc ctgcgcggac	1200
tctgggtggag caggcagcaa acttgggtgg gggcctgcaa accttggagg actaaaatcc	1260
aaatctgcgt cttctgggtg cttgaaggca aaggcgcaag ccccttcgaa aattaatgga	1320
accacagttg ttacatctaa agaaggcttc aagcatgatg atgatctacc ttgcctccc	1380
cccagaactt ttatcaacca gttgcctgat tggagcatgc ttcttgctgc tatcacaaca	1440
attttcttgg ccgctgaaaa gcagtggatg atgcttgatt ggaagccacg gcgacctgac	1500
atgcttattg accccttttg gataggaaaa attgttcagg atggtcttgt gttccgtgaa	1560
aacttttcta ttagatcata tgagatttgt gctgatcgta ccgcatctat agaaacagta	1620
atgaaccatt tgcaagtaag tccgtcctca tacaagtga tctttatgat cttcagagat	1680
gagtatgctt tgactaagat agggctgttt atttagacac tgtaattcaa tttcatatat	1740
agataatatc attctgttgt tacttttcat actatattta tatcaactat ttgcttaaca	1800
acaggaaaact gcacttaatc atgttaaaaag tgctgggctt cttgggtgatg gctttgggtc	1860
cacgccagaa atgtgcaaaa agaacttgat atgggtgggt actcggatgc aggttgttgt	1920
ggaacgctat cctacatggt tagtcatcta gattcaacca ttacatgtga tttgcaatgt	1980
atccatgtta agctgctatt tctctgtcta ttttagtaat ctttatgagg aatgatcact	2040
cctaaatata ttcattgtaa ttattgagac ttaattatga gaacaaaat gctttggaaa	2100
tttgtctggg atgaaaattg attagataga caagctttat acatgatgaa ctatgggaaa	2160
ccttgtgcaa cagagctatt gatctgtaca agagatgtag tatagcatta attacatgtt	2220
attagataag gtgacttata cttgtttaat tattgtaaaa atagaagctg atactatgta	2280
ttctttgcat ttgttttctt accagttata tataccctct gttctgtttg agtactacta	2340
gatgtataaa gaatgcaatt attctgactt cttgggtgtt gggtgaagtt agataagcta	2400
ttagtattat tatggttatt ctaaacttaa ttatctgaaa ttgtgtgtct atatttgctt	2460
caggggtgac atagttcaag tggacacttg ggtttctgga tcaggaaga atggtatgcg	2520

tcgtgattgg	cttttacgtg	actgcaaaac	tggtgaaatc	ttgacaagag	cttccaggta	2580
gaaatcattc	tctgtaattt	tccttcccct	ttccttctgc	ttcaagcaaa	ttttaagatg	2640
tgtatcttaa	tgtgcacgat	gctgattgga	cacaatttta	aatctttcaa	acatttacia	2700
aagttatgga	accctttctt	ttctctcttg	aagatgcaaa	tttgtcacga	ctgaagtttg	2760
aggaaatcat	ttgaattttg	caatgttaaa	aaagataatg	aactacatat	tttgcaggca	2820
aaaacctcta	attgaacaaa	ctgaacattg	tatcttagtt	tatttatcag	actttatcat	2880
gtgtactgat	gcatcacctt	ggagcttgta	atgaattaca	tattagcatt	ttctgaactg	2940
tatgttatgg	ttttggtgat	ctacagtgtt	tggtcatga	tgaataagct	gacacggagg	3000
ctgtctaaaa	ttccagaaga	agtcagacag	gagataggat	cttattttgt	ggattctgat	3060
ccaattctag	aagaggataa	cagaaaactg	actaaacttg	acgacaacac	agcggattat	3120
attcgtaccg	gtttaagtgt	atgtcaacta	gtttttttgt	aattgttgtc	attaatttct	3180
tttcttaa	tatttcagat	gttgctttct	aattagttta	cattatgtat	cttcattctt	3240
ccagtctagg	tgagtgatc	tagatatcaa	tcagcatgtc	aacaatgtga	agtacattga	3300
ctggattctg	gaggtatttt	tctgttcttg	tattctaate	cactgcagtc	cttgttttgt	3360
tgtaaccaa	aggactgtcc	tttgattgtt	tgcagagtgc	tccacagcca	atcttgagga	3420
gtcatgagct	ttcttccgtg	actttagagt	ataggaggga	gtgtggtagg	gacagtgtgc	3480
tggaattccct	gactgctgta	tctggggccg	acatgggcaa	tctagctcac	agtggacatg	3540
ttgagtgcaa	gcatttgctt	cgactcgaaa	atggtgctga	gattgtgagg	ggcaggactg	3600
agtggaggcc	caaacctatg	aacaacattg	gtgttggtga	ccaggttcca	gcagaaagca	3660
cctaagattt	tgaaatgggt	aacggttgga	gttgcatcag	tctccttgct	atgtttagac	3720
ttattctggc	ctctggggag	agttttgctt	gtgtctgtcc	aatcaatcta	catatcttta	3780
tatccttcta	atttgtgtta	ctttggtggg	taagggggaa	aagctgcagt	aaacctcatt	3840
ctctctttct	gctgctccat	atttcatttc	atctctgatt	gcgctactgc	taggctgtct	3900
tcaatattta	attgcttgat	caaaatagct	aggcatgtat	attattattc	ttttctcttg	3960
gctcaattaa	agatgcaatt	ttcattgtga	acacagcata	actattattc	ttattatttt	4020
tgtatagcct	gtatgcacga	atgacttgtc	catccaatac	aaccgtgatt	gtatgctcca	4080
gctcag						4086

<210> 41  
 <211> 109  
 <212> DNA  
 <213> Glycine max

<220>  
 <223> FATB intron I

<400> 41  
 gtacgcaaac aaatctgcta ttcatctcatt cattcctctt tctctctgat cgcaaactgc 60  
 acctctacgc tccactcttc tcattttctc ttcctttctc gcttctcag 109

<210> 42  
 <211> 836  
 <212> DNA  
 <213> Glycine max

<220>  
 <223> FATB intron II

<400> 42  
 gttctcgatt cttttctctt ttaactttat ttttaaaata ataataatga gagctggatg 60  
 cgtctgttcg ttgtgaattt cgaggcaatg gggttctcat tttcgttaca gttacagatt 120  
 gcattgtctg ctttctctt ctcccttggt tctttgcctt gtctgatttt tcgtttttat 180  
 ttcttacttt taatttttgg ggatggatat tttttctgca ttttttcggt ttgcgatggt 240  
 ttcaggattc cgattccgag tcagatctgc gccggcttat acgacgaatt tgttcttatt 300  
 cgcaactttt cgcttgattg gcttgtttta cctctggaat ctcacacgtg atcaaataag 360  
 cctgctattt tagttgaagt agaatttggt ctttatcgga aagaattcta tggatctggt 420  
 ctgaaattgg agctactggt tcgagttgct atttttttta gtagtattaa gaacaagttt 480  
 gccttttatt ttacattttt ttcctttgct tttgccaaaa gtttttatga tcaactctctt 540  
 ctgtttgtga tataactgat gtgctgtgct gttattattt gttatttggg gtgaagtata 600  
 attttttggg tgaacttggg gcatttttag tccgattgat ttctcgatat catttaaggc 660  
 taagggtgac ctctaccacg cgtttgcgtt tgatgttttt tccatttttt ttttatctca 720  
 tatcttttac agtgtttgcc tatttgcatt tctcttcttt atcccccttc tgtggaaggt 780  
 gggagggaaa atgtattttt tttttctctt ctaacttgcg tatattttgc atgcag 836

<210> 43  
 <211> 169  
 <212> DNA  
 <213> Glycine max

<220>  
 <223> FATB intron III

<400> 43  
 gtaagtccgt cctcatataa gtgaatcttt atgatcttca gagatgagta tgctttgact 60  
 aagatagggc tgtttattta gacactgtaa ttcaatttca tatatagata atatcattct 120  
 gttgttactt ttcatactat atttatatca actatttgct taacaacag 169

<210> 44  
 <211> 328  
 <212> PRT  
 <213> Glycine max

<220>  
 <223> soybean FATB enzyme

<400> 44

Met Glu Glu Gln Leu Leu Ala Ala Ile Thr Thr Ile Phe Leu Ala Ala  
 1 5 10 15

Glu Lys Gln Trp Met Met Leu Asp Trp Lys Pro Arg Arg Pro Asp Met  
 20 25 30

Leu Ile Asp Pro Phe Gly Ile Gly Lys Ile Val Gln Asp Gly Leu Val  
 35 40 45

Phe Arg Glu Asn Phe Ser Ile Arg Ser Tyr Glu Ile Gly Ala Asp Arg  
 50 55 60

Thr Ala Ser Ile Glu Thr Val Met Asn His Leu Gln Glu Thr Ala Leu  
 65 70 75 80

Asn His Val Lys Ser Ala Gly Leu Leu Gly Asp Gly Phe Gly Ser Thr  
 85 90 95

Pro Glu Met Cys Lys Lys Asn Leu Ile Trp Val Val Thr Arg Met Gln  
 100 105 110

Val Val Val Glu Arg Tyr Pro Thr Trp Gly Asp Ile Val Gln Val Asp  
 115 120 125

Thr Trp Val Ser Gly Ser Gly Lys Asn Gly Met Arg Arg Asp Trp Leu  
 130 135 140

Leu Arg Asp Ser Lys Thr Gly Glu Ile Leu Thr Arg Ala Ser Ser Val  
 145 150 155 160

Trp Val Met Met Asn Lys Leu Thr Arg Arg Leu Ser Lys Ile Pro Glu  
 165 170 175

Glu Val Arg Gln Glu Ile Gly Ser Tyr Phe Val Asp Ser Asp Pro Ile  
 180 185 190

Leu Glu Glu Asp Asn Arg Lys Leu Thr Lys Leu Asp Asp Asn Thr Ala  
 195 200 205

Asp Tyr Ile Arg Thr Gly Leu Ser Pro Arg Trp Ser Asp Leu Asp Ile  
 210 215 220

Asn Gln His Val Asn Asn Val Lys Tyr Ile Gly Trp Ile Leu Glu Ser  
 225 230 235 240

Ala Pro Gln Pro Ile Leu Glu Ser His Glu Leu Ser Ser Met Thr Leu  
 245 250 255

Glu Tyr Arg Arg Glu Cys Gly Arg Asp Ser Val Leu Asp Ser Leu Thr  
 260 265 270

Ala Val Ser Gly Ala Asp Met Gly Asn Leu Ala His Ser Gly His Val

275

280

285

Glu Cys Lys His Leu Leu Arg Leu Glu Asn Gly Ala Glu Ile Val Arg  
 290 295 300

Gly Arg Thr Glu Trp Arg Pro Lys Pro Val Asn Asn Phe Gly Val Val  
 305 310 315 320

Asn Gln Val Pro Ala Glu Ser Thr  
 325

&lt;210&gt; 45

&lt;211&gt; 1856

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;223&gt; soybean FATB partial genomic clone

&lt;400&gt; 45

```

ttagggaaac aacaaggacg caaaatgaca caatagccct tcttcctgt ttccagcttt      60
tctccttctc tctctccatc ttcttcttct tcttcactca gtcaggtagc caaacaaatc      120
tgctattcat tcattcattc ctctttctct ctgatcgcaa actgcacctc tacgctccac      180
tcttctcatt ttctcttcct ttctcgcttc tcagatccaa ctctcagat aacacaagac      240
caaaccgct ttttctgcat ttctagacta gacgtttctac cggagaaggt tctcgattct      300
tttctctttt aactttatth ttaaaataat aataatgaga gctggatgag tctgttcgtt      360
gtgaatttcg aggcaatggg gttctcattt tcgttacagt tacagattgc attgtctgct      420
ttctcttctc cccttggttc ttgacctgtg ctgatttttc gtttttattt cttactttta      480
atthttgggg atggatattt tttctgcatt ttttcggttt gogatgtttt caggattccg      540
attccgagtc agatctgagc cggcttatac gacgaatttg ttcttattcg caacttttcg      600
cttgattggc ttgttttacc tctggaatct cacacgtgat caaataagcc tgctatttta      660
gttgaagtag aatttggtct ttatcggaag gaattctatg gatctgttct gaaattggag      720
ctactgtttc gagttgctat tttttttagt agtattaaga acaagtttgc cttttatttt      780
acattttttt cctttgcttt tgccaaaagt ttttatgata actctcttct gtttgtgata      840
taactgatgt gctgtgctgt tattatttgt tatttggggt gaagtataat ttttgggtg      900
aacttgagc atttttagtc cgattgattt ctcgatatca ttttaaggcta aggttgacct      960
ctaccacgag tttgcgtttg atgttttttc catttttttt ttatctcata tcttttacag     1020
tgtttgcta tttgcatttc tcttctttat cccctttctg tggaagggtg gagggaaaat     1080
gtattttttt tttctcttct aacttgagta tattttgcat gcagcgacct tagaaattca     1140
ttatggtggc aacagctgct acttcatcat ttttcctgt tacttcaccc tcgccgagct     1200
ctggtggagc aggcagcaaa cttggtggtg ggcccgcaaa ccttggagga ctaaaatcca     1260

```

aatctgcgtc ttctggtggc ttgaaggcaa aggcgcgaagc cccttcgaaa attaattggaa 1320  
ccacagttgt tacatctaaa gaaggcttca agcatgatga tgatctacct tcgcctcccc 1380  
ccagaacttt tatcaaccag ttgcctgatt ggagcatgct tcttgctgct atcacaacaa 1440  
ttttcttggc cgctgaaaag cagtggatga tgcttgattg gaagccacgg cgacctgaca 1500  
tgcttattga cccctttggg ataggaaaaa ttgttcagga tggctcttggtg ttccgtgaaa 1560  
acttttctat tagatcatat gagattggtg ctgatcgta cgcactctata gaaacagtaa 1620  
tgaaccattt gcaagtaagt cgcctctcat acaagtgaat ctttatgatc ttcagagatg 1680  
agtatgcttt gactaagata gggctgttta tttagacact gtaattcaat ttcatatata 1740  
gataatatca ttctgttggt acttttcata ctatatttat atcaactatt tgcttaacaa 1800  
caggaaactg cacttaatca tgtaaaaagt gctgggcttc ttggtgatgg ctggta 1856

<210> 46  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer F1

<400> 46  
gcggccgccc cgggtaggg aaacaacaag gacg 34

<210> 47  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer F2

<400> 47  
gcggccgccc cgggcagtca gatccaactc ctca 34

<210> 48  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> Oligonucleotide primer F3

<400> 48  
gcggccgccc cgggattggt gctgatcgta ccgc 34

<210> 49  
<211> 38  
<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide primer R1

<400> 49

gcggccgcgg tacccccct tacccaccaa agtatcac

38

<210> 50

<211> 34

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide primer R2

<400> 50

gcggccgcgg taccaaactc tccccaggga acca

34

<210> 51

<211> 34

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide primer R3

<400> 51

gcggccgcgg taccagccat caccaagaag ccca

34

<210> 52

<211> 37

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide primer 18133

<400> 52

gaattcctcg agtcgattc ttttctcttt taacttt

37

<210> 53

<211> 37

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide primer 18134

<400> 53

gaattcctcg agcatgcaaa atatacgcaa gttagaa

37

<210> 54

<211> 854

<212> DNA

<213> Artificial

&lt;220&gt;

&lt;223&gt; PCR product containing soybean FATB intron II

&lt;400&gt; 54

```

gaattcctcg agctcgattc ttttctcttt taactttatt tttaaaataa taataatgag      60
agctggatgc gtctgttcgt tgtgaatttc gaggcaatgg ggttctcatt ttcgttacag      120
ttacagattg cattgtctgc tttcctcttc tcccttggtt ctttgccctg tctgattttt      180
cgttttttatt tcttactttt aatttttggg gatggatatt ttttctgcat ttttccggtt      240
tgcgatgttt tcaggattcc gattccgagt cagatctgcg ccggcttata cgacgaattt      300
gttcttattc gcaacttttc gcttgattgg cttgttttac ctctggaatc tcacacgtga      360
tcaaataagc ctgctatttt agttgaagta gaatttggtc tttatcggaa agaattctat      420
ggatctgttc tgaaattgga gctactgttt cgagttgcta ttttttttag tagtattaag      480
aacaagtttg ctttttattt tacatttttt tcctttgctt ttgccaaaag tttttatgat      540
cactctcttc tgtttgatgat ataactgatg tgctgtgctg ttattatttg ttatttgggg      600
tgaagtataa ttttttgggt gaacttgagg catttttagt ccgattgatt tctcgatata      660
atttaaggct aagggtgacc tctaccacgc gtttgogttt gatgtttttt ccattttttt      720
tttatctcat atcttttaca gtgtttgcct atttgcatth ctcttcttta tcccccttct      780
gtggaagggt ggagggaaaa tgtatttttt ttttctcttc taacttgcgt atattttgca      840
tgctcgagga attc                                     854

```

&lt;210&gt; 55

&lt;211&gt; 1688

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;223&gt; soybean FATB cDNA

&lt;400&gt; 55

```

acaattacac tgtctctctc ttttccaaaa ttagggaaac aacaaggacg caaaatgaca      60
caatagccct tcttccctgt ttccagcttt tctccttctc tctctctcca tcttcttctt      120
cttcttcaact cagtcagatc caactcctca gataacacaa gaccaaaccg gctttttctg      180
catttctaga ctagacgttc tacoggagaa gcgaccttag aaattcatta tgggtggcaac      240
agctgctact tcatcatttt tccctgttac ttcaccctcg ccggactctg gtggagcagg      300
cagcaaactt ggtgggtggc ctgcaaacct tggaggacta aaatccaaat ctgcgtcttc      360
tgggtggcttg aaggcaaagg cgcaagcccc ttcgaaaatt aatggaacca cagttgttac      420
atctaaagaa agcttcaagc atgatgatga tctaccttcg cctcccccca gaacttttat      480
caaccagttg cctgattgga gcatgcttct tgctgctatc acaacaattt tcttggccgc      540

```



tgaaaagcag tggatgatgc ttgattggaa gccacggcga cctgacatgc ttattgaccc	600
ctttgggata ggaaaaattg ttcaggatgg tcttgtgttc cgtgaaaact tttctattag	660
atcatatgag attggtgctg atcgtaccgc atctatagaa acagtaatga accatttgca	720
agaaactgca cttaatcatg ttaaaagtgc tgggcttctt ggtgatggct ttggttccac	780
gccagaaatg tgcaaaaaga acttgatatg ggtggttact cggatgcagg ttgtggtgga	840
acgctatcct acatggggtg acatagttca agtggacact tgggtttctg gatcagggaa	900
gaatggtatg cgtcgtgatt ggcttttacg tgactccaaa actggtgaaa tcttgacaag	960
agcttccagt gtttgggtca tgatgaataa gctaacacgg aggctgtcta aaattccaga	1020
agaagtcaga caggagatag gatcttattt tgtggattct gatccaattc tggaagagga	1080
taacagaaaa ctgactaaac ttgacgacaa cacagcggat tatattcgta ccggtttaag	1140
tcctaggtgg agtgatctag atatcaatca gcatgtcaac aatgtgaagt acattggctg	1200
gattctggag agtgctccac agccaatctt ggagagtcac gagctttctt ccatgacttt	1260
agagtatagg agagagtgtg gtagggacag tgtgctggat tccctgactg ctgtatctgg	1320
ggccgacatg ggcaatctag ctcacagcgg gcatgttgag tgcaagcatt tgcttcgact	1380
ggaaaatggt gctgagattg tgaggggcag gactgagtgg aggcccaaac ctgtgaacaa	1440
ctttggtgtt gtgaaccagg ttccagcaga aagcacctaa gatttgaaat ggtaaacgat	1500
tggagttgca tcagtctcct tgctatgttt agacttattc tggttccctg gggagagttt	1560
tgcttgtgtc tatccaatca atctacatgt ctttaaatat atacaccttc taatttgtga	1620
tactttggtg ggtaaggggg aaaagcagca gtaaattctca ttctcattgt aattaaaaaa	1680
aaaaaaaa	1688

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number  
**WO 2004/001000 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/09,  
15/63, 15/82, 15/90, A01H 5/00

(21) International Application Number:  
PCT/US2003/019437

(22) International Filing Date: 20 June 2003 (20.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/390,186 21 June 2002 (21.06.2002) US

(71) Applicant: MONSANTO TECHNOLOGY LLC  
[US/US]; 800 N. Lindbergh Boulevard, St. Louis, MO  
63167 (US).

(72) Inventor: FILLATTI, Joanne, J.; 36757 Russell Blvd.,  
Davis, CA 95616 (US).

(74) Agents: MARSH, David, R. et al.; Arnold & Porter, Attn:  
IP Docketing Dept., Room 1126B, 555 Twelfth Street,  
N.W., Washington, DC 20004-1206 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
12 August 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: INTRON DOUBLE STRANDED RNA CONSTRUCTS AND USES THEREOF

(57) Abstract: The present invention is in the field of plant genetics and provides agents capable of gene-specific silencing. The present invention specifically provides double-stranded RNA (dsRNA) agents, methods for utilizing such agents and plants contain-  
ing such agents.

WO 2004/001000 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/19437

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(7) : C12N 15/09, 15/63, 15/82, 15/90; A01H 5/00		
US CL : 435/320.1, 468; 800/278, 281, 285, 286		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/320.1, 468; 800/278, 281, 285, 286		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, Agricola, CAPLUS, BIOSIS		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LEVIN et al. Methods of Double-Stranded RNA-Mediated Gene Inactivation in Arabidopsis and Their Use to Define an Essential Gene in Methionine Biosynthesis. Plant Mol. Biol. 2000, Vol. 44, pages 759-775, see pages 764-768.	1-4, 6, 7, 9-10, 17
Y	STOUTJESDIJK et al. hpRNA-Meditated Targeting of the Arabidopsis FAD2 Gene Gives Highly Efficient and Stable Silencing. Plant Physiology. August 2002, Vol. 129, pages 1723-1731, see pages 1724-1726.	1-7, 9-14, 17
P, Y	US 6,573,099 B2 (GRAHAM) 03 June 2003 (03.06.2003), column 14, line 60 to column 23, line 18, column 25, line 60 to column 28, line 65.	1-4, 6, 7, 9, 10, 17
P, T, Y	US 6,506,559 B1 (FIRE et al.) 14 January 2003 (14.01.2003), column 2, line 45 to column 4, line 16, column 26, line 29 to column 28, line 20.	1-4, 6, 7, 9, 10, 17
Y	CHUANG et al. Specific and Heritable Genetic Interference by Double-Stranded RNA in Arabidopsis Thaliana. PNAS. 25 April 2000, Vol. 97, No. 9, pages 4985-4990, see whole document.	1-4, 6, 7, 9, 10, 17
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 09 February 2004 (09.02.2004)		Date of mailing of the international search report <b>21 JUN 2004</b>
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer <i>Asitwan Mehta</i> Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/19437

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, 9-14, 17

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

## INTERNATIONAL SEARCH REPORT

PCT/US03/19437

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-7, 9-14, 17, drawn to a first product, a nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule, wherein one strand is coded by a portion of DNA having identity to a at least one transcribed intron of a gene, a transformed plant having in its genome said nucleic acid construct; and a first method, for reducing expression of a protein encoded by a target gene in a plant.

Group II, claim(s) 8, 15, 16, drawn to a second product, a transformed non-plant cell or organism having in its genome an introduced nucleic acid construct comprising DNA which is transcribed into RNA that forms at least one double-stranded RNA molecule; and a second method, for reducing expression of a protein encoded by a target gene in a mammal.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the transformed plant and method involving plant transformation of Group I are not shared with the non-plant organisms and method comprising transformation of mammalian cells of Group II.